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ERRATUM 
 
Moore, T. (2007). Monograph No. 14: Working estimates of the social costs per gram and per 
user for cannabis, cocaine, opiates and amphetamines. DPMP Monograph Series. Sydney: National 
Drug and Alcohol Research Centre. 
 
In the original monograph, there is a calculation error in the way the weights for cannabis from 
Clements and Daryal (1999) were converted from ounces to grams and kilograms, resulting in the 
weights being overstated by a factor of 10.  The main estimate for the amount of cannabis 
changes from 2,815,008 kilograms to 281,501 kilograms, and the main estimate for the social cost 
per kilogram of cannabis changes from $1,106 per kilogram to $11,064 per kilogram.  There are a 
number of other changes, as specified below.  The social costs per user are unchanged. 
 
p.3 
In the table, the Cannabis column should read: "$3,115; 281,501; $11,064; $11". 
In the paragraph below the table: "for cannabis the 95% confidence intervals around the social 
cost per annum per pure gram were between $4.47 and $19.86;...". 
p.23 
In Table 6, the bottom value of the first column should read: "281,501(g)". 
p.24 
The last sentence should read "On this basis, it is estimated that 281,501 kilograms of marijuana 
is consumed in Australia." 
p.26 
In the second sentence of the bottom paragraph, "more than 10,000 times" should read "more 
than 1,000 times". 
p.27 
In Table 9, the first row should read "Total costs - all drug users ($m)".  Also, the Cannabis 
column should read: "$3,115; 281,501; $11,064; $11". 
p.29 
In Table 10 in the last subsection "Amount consumed (pure except cannabis)", the Cannabis 
column should read "281,501; 173,316; 406,603; 698,639". 
p.30 
In Table 11 in the second subsection "Per Weight estimates", the Cannabis column should read 
"$11,064; $4,471; $9,894; $19,859; $11.06; $4.47; $9.89; $19.86". 
p.50 
In Table A3.3, the top row should read: 93,834; 281,501; 844,503. 
 
These changes have been incorporated into the electronic version of the monograph. 
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THE DRUG MODELLING POLICY PROGRAM 
 
This monograph forms part of the Drug Policy Modelling Program (DPMP) Monograph Series. 
 
Drugs are a major social problem and are inextricably linked to the major socio-economic issues 
of our time. Our current drug policies are inadequate and governments are not getting the best 
returns on their investment. There are a number of reasons why: there is a lack of evidence upon 
which to base policies; the evidence that does exist is not necessarily analysed and used in policy 
decision-making; we do not have adequate approaches or models to help policy-makers make 
good decisions about dealing with drug problems; and drug policy is a highly complicated and 
politicised arena. 
 
The aim of the Drug Policy Modelling Program (DPMP) is to create valuable new drug policy 
insights, ideas and interventions that will allow Australia to respond with alacrity and success to 
illicit drug use. DPMP addresses drug policy using a comprehensive approach, that includes 
consideration of law enforcement, prevention, treatment and harm reduction. The dynamic 
interaction between policy options is an essential component in understanding best investment in 
drug policy.  
 
DPMP conducts rigorous research that provides independent, balanced, non-partisan policy 
analysis. The areas of work include: developing the evidence-base for policy; developing, 
implementing and evaluating dynamic policy-relevant models of drug issues; and studying policy-
making processes in Australia. 
 
Monographs in the series are: 
 
01. What is Australia’s “drug budget”? The policy mix of illicit drug-related government 
spending in Australia 
02. Drug policy interventions: A comprehensive list and a review of classification 
schemes 
03. Estimating the prevalence of problematic heroin use in Melbourne 
04. Australian illicit drugs policy: Mapping structures and processes 
05. Drug law enforcement: the evidence  
06. A systematic review of harm reduction 
07. School based drug prevention: A systematic review of the effectiveness on illicit 
drug use 
08. A review of approaches to studying illicit drug markets 
09. Heroin markets in Australia: Current understandings and future possibilities 
10. Data sources on illicit drug use and harm in Australia 
11. SimDrug: Exploring the complexity of heroin use in Melbourne  
12. Popular culture and the prevention of illicit drug use: A pilot study of popular 
music and the acceptability of drugs 
13. Scoping the potential uses of systems thinking in developing policy on illicit drugs 
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14. Working estimates of the social costs per gram and per user for cannabis, cocaine, 
opiates and amphetamines  
15. Priority areas in illicit drug policy: Perspectives of policy makers 
 
DPMP strives to generate new policies, new ways of making policy and new policy activity and 
evaluation. Ultimately our program of work aims to generate effective new illicit drug policy in 
Australia. I hope this Monograph contributes to Australian drug policy and that you find it 
informative and useful. 
 
 
 
Alison Ritter 
Director, DPMP 
ii 
SOCIAL COSTS BY DRUG TYPE 
ACKNOWLEDGEMENTS 
 
This research has been done as part of the Drug Policy Modelling Program. It has been funded 
by a research grant from the Australian Federal Police and by the Colonial Foundation Trust. I 
am grateful to Shannon Monagle for excellent research assistance, and Jonathan Caulkins for 
doing the sensitivity analysis simulations. Jonathan Caulkins, Alison Ritter, Peter Reuter and 
Lance Smith provided helpful comments. All errors or omissions are my own. 
 
The Drug Use Monitoring in Australia (DUMA) data used in this report were made available by 
the Australian Institute of Criminology and the DUMA steering committees in New South 
Wales, Queensland, South Australia and Western Australia. The DUMA program is funded under 
the Australian Government’s National Illicit Drug Strategy, and the South Australian Attorney-
General’s Department funds one of the South Australian sites. These data were originally 
collected by data collection agencies at each of the sites around Australia, with the assistance of 
police services, for the Australian Institute of Criminology. Neither the collectors, police services 
nor the AIC bear any responsibility for the analyses or interpretations presented herein. 
 
The Australian Bureau of Statistics mortality data used was held by the Drug Statistics and 
Epidemiology Program at the Turning Point Alcohol and Drug Centre. Access was obtained 
after ethical approval was sought and granted from the Human Research Ethics Committee at 
the Victorian Department of Human Services. 
iii 
SOCIAL COSTS BY DRUG TYPE 
TABLE OF CONTENTS 
 
Summary ................................................................................................................................. 1 
Introduction ............................................................................................................................ 5 
Conceptual and methodological issues ............................................................................... 6 
Social costs related to illicit drugs .......................................................................................................... 6 
The incidence and prevalence of illicit drugs ....................................................................................... 7 
Drug categories ......................................................................................................................................... 7 
Prevalence and consumption estimates ................................................................................................. 7 
Dependence ............................................................................................................................................... 8 
Consistency of cost and other information .......................................................................................... 8 
Use of the results ...................................................................................................................................... 8 
Health effects .......................................................................................................................... 9 
Data and methods .................................................................................................................................... 9 
Results ...................................................................................................................................................... 12 
Crime effects ......................................................................................................................... 13 
Data and methods .................................................................................................................................. 13 
Results ...................................................................................................................................................... 15 
Road accidents ..................................................................................................................... 17 
Welfare and labour market effects ...................................................................................... 18 
Prevalence estimates ........................................................................................................... 19 
Opiate/heroin users ............................................................................................................................... 19 
Amphetamine users ................................................................................................................................ 20 
Cannabis users ......................................................................................................................................... 21 
Cocaine users ........................................................................................................................................... 21 
Consumption-based market estimates .............................................................................. 22 
Heroin consumption .............................................................................................................................. 22 
Amphetamine consumption ................................................................................................................. 23 
Cocaine consumption ............................................................................................................................ 24 
Cannabis consumption .......................................................................................................................... 24 
Results .................................................................................................................................. 25 
Social costs per drug user ...................................................................................................................... 25 
Social costs per amount consumed ...................................................................................................... 26 
Sensitivity analysis ................................................................................................................................... 27 
iv 
SOCIAL COSTS BY DRUG TYPE 
Conclusion and discussion ................................................................................................. 31 
References ............................................................................................................................ 33 
Appendix 1: Health-related calculations ............................................................................ 37 
Appendix 2: Calculation of crime costs ............................................................................. 40 
Appendix 3: Sensitivity analysis ......................................................................................... 46 
v 
SOCIAL COSTS BY DRUG TYPE 
vi 
LIST OF TABLES 
 
Table 1: Health categories in Mathers et al. (1999) and how assigned to illicit drug types ............. 11 
Table 2: Drug-attributable disability adjusted life years (DALY), converted to annual cost, by 
illicit drug type ........................................................................................................................... 12 
Table 3: Drug-attributable crime calculated as annual social cost ($million), by illicit drug type ... 16 
Table 4: Annual road accident cost attribution between dependent and non-dependent users ..... 17 
Table 5: Illicit drug prevalence estimates, by level of dependence and illicit drug type ................... 19 
Table 6: Estimates of the annual quantity consumed in pure terms (except cannabis), by illicit 
drug type ..................................................................................................................................... 23 
Table 7: Total social costs per year ($million), by illicit drug type ...................................................... 25 
Table 8: Annual social costs per drug user, by level of dependence and illicit drug type ................ 26 
Table 9: Annual social costs per pure kilogram and pure gram, by illicit drug type ......................... 27 
Table 10: Sensitivity analysis, 95% confidence intervals: Costs, prevalence, market size ................ 28 
Table 11: Sensitivity analysis, 95% confidence intervals: Per user and weight estimates ................ 30 
 
Table A1.1: Years lost as a result of a disability (YLD), by illicit drug type ...................................... 37 
Table A1.2: Drug-attributable potential years of life lost (YLL), by illicit drug type ....................... 38 
Table A1.3: Cost attribution between dependent and non-dependent users, $million .................... 39 
Table A2.1: DUMA income-generating offences, by dependence and attribution .......................... 40 
Table A2.2: Fractions of income-generating crimes attributed to illicit drug use ............................. 41 
Table A2.3: Cost of income-generating crime attributed to illicit drug use ($million)..................... 42 
Table A2.4: Other DUMA offences, by dependence and attribution ................................................ 43 
Table A2.5: Fractions of other crimes attributed to illicit drug use .................................................... 44 
Table A2.6: Cost of other crimes attributed to illicit drug use ($million) .......................................... 45 
Table A3.1: Sensitivity analysis for health, crime, road accident and labour costs ........................... 46 
Table A3.2: Sensitivity analysis for numbers of drug users .................................................................. 48 
Table A3.3: Sensitivity analysis for the market-sizing estimates .......................................................... 50 
 
SOCIAL COSTS BY DRUG TYPE 
SUMMARY 
 
Purpose of the work 
This work represents a first step in estimating the different social costs associated with different 
illicit drugs. More specifically, the report sets out in detail the annual costs in Australia (circa 
2004) associated with opiates, amphetamines, cocaine, and other illicit drugs separately across two 
major classes of social costs: health and crime. The cost estimates are further broken down 
between dependent users and non-dependent users. These are then combined with prevalence 
and consumption to generate estimates of the: 
1. social costs per drug user by drug type; and 
2. social costs per kilogram (or gram) for each drug type. 
 
The work is important because, by generating estimates such as these, we can begin to evaluate 
different policy responses in terms of cost savings to the community. Being able to specify the 
social costs per gram and per user for the main classes of illicit drugs means that we can then 
evaluate policy responses – such as the potential cost savings of reducing the supply of a specific 
drug by X kilograms; or the cost savings of decreasing the number of dependent drug users by Y.  
 
Social costs associated with health and crime by different drug types 
Firstly, Moore estimated the total health and crime costs per annum, associated with dependent 
and non-dependent use of cannabis, cocaine, opiates and amphetamine.  
 
For health (disability adjusted life years), the costs are distributed such: 
 
 Cannabis Cocaine Opiates Amphet. 
Dependent users ($million) p.a. $ 1,195 $ 113 $ 2,386 $ 274 
Non-dependent users ($million) p.a. $ 0.067  $ 24.7 $ 137 $ 67.5  
 
As can be seen, in relation to health costs, dependent opiate users bear the largest costs ($2,386 
million p.a.), followed by dependent cannabis users. Non-dependent users’ health costs are 
negligible relative to the dependent users. 
 
For crime costs, the costs are distributed such: 
 
 Cannabis Cocaine Opiates Amphet. 
Dependent users ($million) p.a. $ 1,601 $ 135 $ 1,714  $ 2,795 
Non-dependent users ($million) p.a. $ 319 $ 26.7 $ 29.6 $ 244 
 
In the case of social costs attributable to crime, dependent amphetamine users generate the 
largest cost burden to our community ($2,795 million), with cannabis and opiates at roughly equal 
crime costs per annum. Again, the non-dependent user annual costs are significantly less than for 
dependent users. Indeed dependent drug users account for more than 80% of the total 
identifiable social costs (health and crime). 
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The social costs of road accidents are also reported herein. The next step in the work was to use 
these cost calculations, and combine them with both prevalence estimates and consumption 
estimates in order to estimate: 
1. social cost per drug user (by drug type); and 
2. social cost per kilogram (or gram) for each drug type. 
 
Estimates of social cost per drug user  
To evaluate policy responses it is helpful to have some estimate of the annual social cost of 
opiate, amphetamine, cocaine and cannabis users. Thus, if an intervention claimed to reduce the 
number of users by 10%, the potential cost savings could be calculated using the figures below.  
 
The results per drug user are summarised here. At a simplistic level, the total costs (health, crime, 
road accidents) for cannabis ($3,115m per annum) can be divided by the total number of users 
(approximately 1.9 million users), which results in a social cost per cannabis user of $1,631 per 
annum. The results for the four drug classes using this summary approach are: 
 
 Cannabis Cocaine Opiates Amphet. 
Total costs – all drug users ($million) $ 3,115 $ 299 $ 4,574 $ 3,731 
Number of users 1,910,075  176,346  149,299  568,757 
Social cost per user ($) $ 1,631  $ 1,699  $ 30,633 $ 6,560  
 
However, this does not acknowledge the significant social cost differences between dependent 
and non-dependent drug users. Therefore a more detailed picture can be gained by separating 
dependent from non-dependent users. These results are presented in the table below. As can be 
seen, dependent opiate users annual social cost per user is $105,342 compared to an annual social 
cost per non-dependent opiate user of $1,965. 
 
Annual social cost (health, crime and road accidents) per user by drug type, dependent and 
non-dependent users 
 Cannabis Cocaine Opiates Amphet. 
Dependent drug users     
Costs – dependence ($million) $ 2,796 $ 248 $ 4,361 $ 3,272 
Number of users 247,500  13,892  41,401  73,257  
Social cost per dep. user $ 11,296 $ 17,852 $ 105,342 $ 44,665 
Non-dependent drug users     
Costs – non-dependence ($million) $ 319 $ 51 $ 212 $ 459 
Number of users 1,662,575  162,454  107,898  495,500  
Social cost per non-dep. user  $ 192 $ 314 $ 1,965 $ 926 
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Sensitivity analyses (95% confidence intervals) revealed that the plausible range for the estimates 
for dependent users of cannabis was between $6,998 and $17,437 social cost per annum; for 
cocaine between $12,107 and $24,548 social cost per annum; for opiates between $55,330 and 
$115,222; and for amphetamines between $18,258 and $48,757. (The report details the sensitivity 
analysis for the non-dependent users).  
 
Estimates of social cost per kilogram of drug 
An alternate way of estimating the effect of policy responses is to consider a social cost per 
kilogram of drug, which is a metric that may be more useful for supply reduction interventions. 
The table below provides the results (the distinction between dependent and non-dependent 
users is not relevant here as the calculations are driven purely by quantity consumed). 
  
Annual social costs per pure kilogram and pure gram, by illicit drug type 
 Cannabis Cocaine Opiates Amphet. 
Total costs – all drug users ($million) $ 3,115 $ 299 $ 4,574 $ 3,731 
Amount consumed per year (kg) 281,501 830 335 575 
Social cost per kilogram $ 11,064 $ 360,241 $ 13,653,731 $ 6,488,695 
Social cost per gram $ 11 $ 360 $ 13,653 $ 6,488 
 
Again, it is important to consider the plausible range for these figures of social cost per annum 
per pure gram (kilogram figures are in the report): for cannabis the 95% confidence intervals 
around the social cost per annum per pure gram were between $4.47 and $19.86; for cocaine 
between $147.00 and $540.00; for opiates between $4,100 and $14,891; and for amphetamines 
between $1,710 and $6,983. 
 
Caveats and important considerations 
There are several significant and important caveats. First, the analysis depends on the assumption 
that social costs can be linked to particular types of drugs, and a decrease in how much that drug 
is used will decrease social costs. While this is a reasonable assumption for small changes in use, it 
would certainly not hold for large changes.  
 
Second, it is important to understand that all social costs are allocated to illicit drugs as if their 
consumption has been constant over time. This has clearly not been the case, but there is not 
enough information to allocate current social costs between current and past use. Interpretations 
related to drugs whose use is known to have varied a lot recently – especially heroin and 
amphetamine – require an added degree of caution. 
 
Third, there are significant gaps in our knowledge about the relationships between drug use and 
social costs. Even in countries where they have access to longitudinal datasets of the type that 
make such relationships easier to understand, the findings are conflicting and uncertain. In every 
estimate made herein, there are assumptions and caveats (the simplest example is the wide 
variation in estimates of prevalence of different types of drug use). Sensitivity analyses are 
provided in the report and should be used together with the main results.  
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Future directions 
This work represents a first attempt to specify social costs (health, crime and road accidents) by 
four main classes of illicit drugs distinguishing between dependent and non-dependent users. As 
a first endeavour, we expect that there will be substantial refinement required. We would 
encourage researchers and policymakers to use the information here, with appropriate caveats, in 
order to assess its usefulness to advancing illicit drug policy in Australia. We would also 
encourage critical review and would be pleased to receive feedback.  
 
Alison Ritter, 
Director, Drug Policy Modelling Program 
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INTRODUCTION 
 
Illicit drug use is an area of major policy concern in Australia. It has been estimated that 
approximately $1.3 billion is spent on drug policies by Australian governments, with more again 
spent on dealing with the consequences of illicit drug use. The majority is spent on enforcing 
drug laws, while significant amounts are spent on preventing drug use and treating drug users 
(Moore, 2005). 
 
Despite the extent of the resources committed to minimising drug use and its harmful effects, 
there is little information available for setting policy priorities both within and across programs. 
Cost-of-illness studies, the major sources of information on the economic effects of illicit drug 
use, provide little policy guidance (Moore & Caulkins, 2006). The only major requirement made 
of them is that they supply an estimate of what a nation would save if there were no illicit drug 
use. Collins and Lapsley (2002), in the most recent Australian study, do not attribute social costs 
to particular illicit drug types and provide little insight into the causal relationships between drug 
use and social costs. 
 
The Australian Federal Police (AFP) has developed a set of measures that provide more 
assistance in policy development and priority setting than the cost-of-illness studies. They have 
attempted to assess the impact of their activities on societal wellbeing by assessing the “social 
cost per kilogram” of four major categories of illicit drugs: opiates, cannabis, amphetamines and 
cocaine (and sometimes other drugs).  
 
The first estimate considered illicit drugs seized by the AFP during a two-year period during 1999 
and 2001, and used the street value of heroin, cocaine and amphetamines as a proxy for their 
social costs (McFadden, Mwesigye & Williamson, 2002). A second estimate, which included 
estimates for marijuana, was made for the 2002-03 financial year by McFadden (2006). This 
estimate was based on social cost figures taken primarily from Collins and Lapsley (2002). 
 
Reuter (1999) once described a cost-of-illness study as “an exercise in hubris”, given that the 
information required to properly estimate the social costs caused by illicit drug use exceeds the 
information available to researchers. It should be noted that the exercises undertaken previously 
by the AFP, now updated and extended here, are more ambitious than cost-of-illness studies. In 
this report, there is an effort to lessen the “hubris” required by being explicit about assumptions 
and conducting sensitivity analyses, but users of such estimates should be aware of how inexact 
the estimates may be. On the other hand, critics should understand that, for government agencies 
having to make decisions about where to deploy their resources and having to meet outcome 
reporting requirements, such an approach has at least the potential to get agencies to focus their 
attention on the drugs and drug users generating the greatest harm. 
 
The report is set out as follows. Conceptual and methodological issues are discussed in the next 
section. The social costs generated by illicit drug use are estimated in the next four sections: 
health effects (third section), crime effects (fourth section), road accidents (fifth section) and 
labour market outcomes (sixth section). The prevalence of particular types of illicit drug use is 
made in the seventh section and an estimate of the amount of drugs consumed in the eighth 
section. In the ninth section, the preceding estimates are combined to calculate per user and per 
gram estimates. These are discussed in the final section. 
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CONCEPTUAL AND METHODOLOGICAL ISSUES 
 
In broad terms, the exercise is conceptually straightforward: estimate the social costs caused by 
illicit drug use and then identify who generates those social costs and how much of a particular 
drug has been consumed in the process. However, the simplifications required to do this means 
conceptual and methodological issues are important for understanding the results presented later 
in the report. 
 
Social costs related to illicit drugs 
An issue of primary importance is to determine what should be regarded as social costs. Earlier 
versions of the AFP’s Drug Harm Index relied on cost-of-illness studies’ estimates of the social 
costs of substance abuse. Such studies have been conducted for more than 20 years, purportedly 
exactly on this topic. However, simply transferring these estimates, such as those contained in 
Collins and Lapsley’s (2002) Australian study, is inappropriate for several reasons. 
 
First, cost-of-illness studies compare the current situation to one where there is no illicit drug use. 
Costs that are essentially fixed, which are not relevant for this exercise, are combined with those 
that are variable.1 Second, cost-of-illness studies generally do not value effects where the available 
information is deemed inadequate, and adopt lower estimates whenever there is some 
uncertainty. Third, a focus on tangible costs means important intangible costs are not included 
(Moore & Caulkins, 2006). 
 
The approach adopted here was to use Collins and Lapsley (2002) as a starting point for the 
identification of social costs. A determination was then made about whether the costs would vary 
on the basis of small changes in the number of drug users or the amount of drug use. A decision 
was made to ignore the costs of policies specifically directed at addressing illicit drug problems 
(these policies are most commonly thought of as comprising: drug law enforcement; specialist 
drug treatment; school and community programs that seek to preventing the uptake of drug use; 
and programs reducing the harmful effects of illicit drug use). The amount spent on some 
policies, such as public health campaigns, would not change with one less drug user. However, it 
is also not clear that the number of arrests or amount spent on drug treatment will diminish if 
one drug user was to be no longer in need of assistance or attention.2 
 
One significant cost included by Collins and Lapsley and in the previous Drug Harm Indices was 
omitted. Collins and Lapsley (2002) considered any illicit drug consumption as “abuse”, as society 
has decided to proscribe their consumption, and counted all expenditure on illicit drugs as a 
social cost. On the other hand, Harwood, Fountain and Livermore (1998), the last major cost-of-
illness study into substance abuse in the United States, confine their analysis to costs relating to 
abuse and dependence (psychiatrically defined) and do not count expenditure as a social cost. 
The inclusion of this kind of private expenditure in public policy analysis seems unwarranted, and 
is not included here. 
 
For costs that were included (costs related to crime, health effects, road accidents and the labour 
market), the best estimate was sought. This included intangible costs, as they reflect what 
                                                 
1 Ideally, marginal costs should be estimated directly. In practice, it is rarely possible. 
2 This would only be the case if treatment places currently meet demand, or if police are arresting all of the people they possibly can. For those that are 
interested or want to include such costs, many of the costs for these policies in Australia are estimated in Moore (2005). 
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someone would do to avoid the pain or suffering they might bear as a result of drug use. 
Fortunately, in the health and crime areas there are estimates of the social costs that are superior 
to Collins and Lapsley’s (2002) estimates. However, this is a difficult exercise; it is still not certain, 
for example, that the intangible costs relating to drug dependence itself are appropriately taken 
into account. 
 
The incidence and prevalence of illicit drugs  
It is important to understand a simplification in this report: all social costs are allocated to illicit 
drugs as if their consumption has been constant over time. This has clearly not been the case, but 
there is not currently enough information to allocate current social costs between, say, the current 
levels of heroin use and the higher levels of use that occurred in the late 1990s. On a per 
kilogram basis, this simplification means actual social costs may be either under-estimated (if 
consumption is increasing) or over-estimated (if consumption is decreasing). In this estimate, this 
issue is most relevant for the social costs of opiates, which are likely to be overstated as 
consumption has recently decreased, and amphetamines, which are likely to be understated as 
consumption has recently increased. 
 
Drug categories 
Throughout the report, drug types are separated into opiates (heroin), amphetamines, cocaine, 
cannabis (marijuana) and other drugs (which includes ecstasy, illegal benzodiazepines, inhalants 
and steroids). Data are drawn from a large number of sources, whose categories are not defined 
in exactly in the same way. This is most pertinent for amphetamines (including 
methamphetamine but generally not ecstasy and related drugs) and opiates (which includes illicit 
methadone, buprenorphine and morphine wherever possible). 
 
Many people use more than one drug (Breen et al., 2004; McKetin et al., 2005). This is dealt with 
by assuming the relationships between drug types and their effects are independent. That is, there 
are no interaction effects between combinations of drugs, such as cocaine and amphetamines or 
opiates and amphetamines. This means the effects can be decomposed in this analysis. It also 
means that assessing the social costs of someone who used more than one drug involves 
summing social costs of the individual drug categories. 
 
Prevalence and consumption estimates 
Previous estimates of prevalence and consumption have relied on the National Drug Strategy 
Household Survey conducted by the Australian Institute for Health and Welfare (AIHW). In this 
report, household survey results are combined with other epidemiological information to adjust 
for the likelihood that household surveys understate the number of dependent drug users. 
 
Most illicit drugs can be consumed in a variety of different ways (e.g. orally, by injection, 
smoking, inhaling, snorting). However, prevalence studies do not normally provide details of 
route of administration when they record how often particular drugs are used. In the market 
estimations, one route of administration is chosen for estimation purposes.  
  
It is important to understand the market estimates developed here are consumption-based 
estimates. They will be different from estimates of the amount of an illicit drug that is imported 
into Australia or produced, as such estimates would have to include quantities that are seized by 
police or lost.  
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Dependence 
The division between users is made on the basis of drug dependence. Dependence is a concept 
used in an explicit way in the crime-related data and in the epidemiological studies used to 
estimate the prevalence of drug use. All of these studies follow DSM-IV criteria for dependence, 
although there are differences in how it is applied in data collection instruments. Where 
dependence was not explicitly used, indirect methods have to be applied to separate dependent 
drug users from other drug users.  
 
Consistency of cost and other information 
Many different data sources are drawn upon in the development of the estimates. The most 
recent information is used; data are generally from the last two or three years. It is important that 
the monetary values are set to a common year; they are updated to 2005 prices using the 
Australian Bureau of Statistics (ABS) chain price index (ABS, 2006a). 
 
There are also broader issues of consistency. One issue is the consistency of drug categories. For 
example, some datasets record the use or effects of heroin, while others record the use or effects 
of opiates, which includes other substances such as methadone and buprenorphine. Similarly, 
some datasets use methamphetamine as a drug category, while others use the broader category of 
amphetamine. Care is taken to match categories as much as possible, yet inconsistencies do 
remain. 
 
Another issue is in the calculation of costs. Costing individual effects of drug use are large 
exercises in themselves, and there is a reliance on existing reports. The authors of these reports 
adopt broadly similar methodologies, but this is another area where there are likely to be 
inconsistencies. 
 
Use of the results 
The attributions are made as carefully as possible. However, there are significant gaps in our 
knowledge about the relationships between drug use and social costs. Even in countries where 
they have access to longitudinal datasets of the type that make such relationships easier to 
understand, the findings are conflicting and uncertain. Sensitivity analysis is conducted and 
should be used together with the main results. 
 
It should also be remembered that average values are used. Studies consistently find that the 
distribution of the social costs of drug use is highly skewed within populations of drug users, with 
the majority of costs generated by a small number of people. The dependence/non-dependence 
division was introduced to address this, but only partially does so. 
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HEALTH EFFECTS 
 
This section estimates the health costs associated with illicit drug use, by drug type (cannabis, 
cocaine, opiates, amphetamines, other) for dependent and non-dependent users. 
 
Ridolfo and Stevenson (2001) indirectly quantified the causal relationship between illicit drug use 
and health in Australia, updating previous studies by English et al. (1995). They identified 26 
conditions as completely or partially caused by illicit drug use and estimated the proportions of 
deaths and hospital separations considered attributable to illicit drug use. 
 
Collins and Lapsley (2002) used this information to estimate the health-related social costs of 
illicit drug use. They measured expenditure on hospital services, medical services, nursing homes, 
pharmaceuticals and ambulance attendances, adjusted for the savings in these areas due to 
premature deaths, and estimated that the social costs amounted to $60 million in 1998-99. 
 
This is a narrow conception of health-related social costs, limited largely to tangible costs borne 
by government. Mathers, Vos and Stevenson (1999) estimated the burden of 176 disease and 
injury categories in 1996 in Australia in terms of disability adjusted life years (DALYs). A DALY 
is equivalent to the loss of one year of life free of disability and disease, combining time lost as a 
result of both premature mortality (potential years of life lost) and years of “healthy” life lost by 
virtue of being in states other than good health (years lost as a result of disability). (Comparisons 
between health conditions and also good health are based on surveys and expert judgements.) 
 
Using English et al.’s (1995) fractions for drug-attributable morbidity and mortality, Mathers et al. 
(1999) estimated that 45,124 DALYs were lost as a result illicit drug use, with 22,031 potential 
years of life lost from premature mortality and 23,093 lost as a result of disability. The potential 
years of life lost were re-estimated for 2004 (the most recent available year) using ABS mortality 
data. The original estimate of the years lost to disability was updated and allocated to particular 
types of drugs on the basis of information on the number of hospital separations in Australia for 
particular conditions in 1996-97 (1996 being the reference year used by Mathers et al, 1999) and 
2003-04 (the most recent available year). Costs identified by Collins and Lapsley (2002) are not 
included; they are subsumed into the broader valuation contained in this willingness to pay 
approach. 
 
DALYs need to be monetised. Abelson (2003) estimated that an appropriate value of a DALY 
for public policy was $108,000 (in 2002 prices). This is based on studies of individuals’ marginal 
willingness to pay to avoid unforeseen death, which is generally justified because it measures the 
relative value placed on goods and can lead to potentially Pareto-efficient outcomes. The same 
average willingness to pay value is applied to all DALYs. This is considered equitable as those 
willing to pay the most may differ from those considered most in need (Abelson, 2003). Updating 
the 2002 figure to 2005 on the basis of the GDP chain price index resulted in a DALY being 
valued at $120,000 (ABS, 2006a). 
 
Data and methods 
The overall estimate of the health-related social costs of illicit drugs consisted of two separate 
estimates: 1) the years lost due to a disability; and 2) the potential years lost due to premature 
mortality. These strategies required different data and methods. 
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Years lost due to a disability 
Updating years lost to a disability required matching drug-attributable health conditions from 
three sources: Mathers et al. (1999) estimate of the burden of disease; Ridolfo and Stevenson’s 
(2001) assessment of drug-attributable health conditions; and the AIHW’s (2006) hospital 
morbidity database (classified by principal diagnosis). The major complications in doing this 
were: 
1. Mathers et al. (1999) and Ridolfo and Stevenson (2001) had used the 9th edition of the 
International Classification of Disease classification system (ICD-9), whereas conditions 
are currently classified using ICD-10; 
2. Mathers et al. (1999) estimate was based on English et al.’s (1995) drug attributable 
conditions, which has subsequently been updated by Ridolfo and Stevenson (2001); 
3. Mathers et al (1999) health conditions classifications did not match up with some of the 
classifications used by English et al. (1995) and Ridolfo and Stevenson (2001); and 
4. Some conditions were not classified to a particular type of drug. 
 
The first one was relatively easy to remedy. Collins and Lapsley (2002) provide, as an appendix, 
the ICD-10 classifications for all of the drug-attributable conditions covered by Ridolfo and 
Stevenson (2001) and the matching ICD-9 codes. The second issue, the need to take account of 
changes between English et al. (1995) and Ridolfo and Stevenson (2001) was addressed by 
applying the earlier fractions to the number of hospital separations in 1996/97, and later fractions 
to separations in 2003/04. 
 
The third issue, the mismatch in classifications between studies, had to be dealt with on a 
condition-specific basis. The other studies had to be made to match the classifications of Mathers 
et al. (1999); it was not possible to decompose their categories given the large number of 
individual calculations that went into the overall DALY calculations. Table 1 shows which 
categories the various health conditions were assigned to. Three conditions – Antepartum 
haemorrhage, Maternal drug dependence and Newborn drug toxicity – were not included in any of Mathers 
et al.’s (1999) categories. The Low birthweight DALYs were extrapolated to these conditions on the 
basis of the number of hospital separations. Table 1 also contains information on how DALYs 
were assigned to drug types where the health condition was related to more than one type of 
drug. 
 
Potential years of life lost due to premature mortality 
The Australian Bureau of Statistics annually produces unit record data on deaths in Australia. 
This includes individuals’ age at death and the primary cause of death, which is classified 
according to the ICD-10 codes. The ICD-10 codes identified by Collins and Lapsley (2002) and 
the allocations outlined in Table 1 were used to identify which deaths should be allocated to 
particular type of illicit drug. 
 
For each death, the age at death was deducted from 81.5 years for males and 85.7 years for 
females. These were the expected lengths of life used by Mathers et al. (1999). Future years are 
discounted relative to current years. A discount rate of 3 per cent per annum was used, which 
was the social discount rate used by Mathers et al. (1999) and Abelson (2003). 
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Table 1: Health categories in Mathers et al. (1999) and how assigned to illicit drug types  
Categories Health conditions How assigned to drug types? 
Heroin dependence & 
harmful use 
Opiate dependence 
Opiate abuse 
Only one drug type in category 
Cannabis dependence & 
harmful use 
Cannabis dependence 
Cannabis abuse 
Only one drug type in category 
Other drug dependence 
& harmful use 
Amphetamine dependence 
Amphetamine abuse 
Cocaine dependence 
Cocaine abuse 
Hallucinogen dependence 
Hallucinogen abuse 
Drug psychoses 
Hospital separations [hospital 
separations for drug psychoses are 
recorded for major drug types in 
ICD-10] 
Benzodiazepine 
dependence and harmful 
use 
None It was not assigned 
Poisoning Poisoning by 
psychostimulants 
Opiate poisoning  
Poisoning by hallucinogens 
Hospital separations 
Suicide and self-inflicted 
injuries 
Suicide Assigned to opiates, as done in 
Ridolfo & Stevenson (2001) 
Low birth weight Low birth weight Assigned to opiates and cocaine on 
the basis of hospital separations and 
attributable fractions 
Hepatitis C Hepatitis non A, and B Conditions were assigned to drug 
types on the basis of injecting drug 
use. Responses to the “drug last 
injected” question in the 2005 
Needle and Syringe Program Survey 
were used (NCHECR, 2005) 
Hepatitis B Hepatitis B 
HIV/AIDS AIS 
Inflammatory heart 
disease 
Infective endocarditis 
Omitted conditions Antepartum haemorrhage 
Maternal drug dependence 
Newborn drug toxicity 
It was not obvious that these 
conditions had been included in the 
other conditions. The DALYS for Low 
birth weight were extrapolated on 
the basis on hospital separations. 
The separations for Antepartum 
haemorrhage attributable to opiates 
and cocaine were directly available, 
so were used to assign the DALYs for 
that condition. The other conditions 
were assigned on the basis of the 
separations for drug dependence for 
each drug type 
Sources: Mathers et al. (1999); Ridolfo & Stevenson (2001); Collins & Lapsley (2002); AIHW (2006). 
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Results 
The detailed calculations for the estimated years lost as a result of a disability and potential years 
of life lost for individual conditions are provided in Appendix 1. The overall results are shown in 
Table 2. The disability adjusted life years were monetised by multiplying each year by 
approximately $120,000. The social costs of opiates were estimated to be approximately $2.5 
billion per annum, cannabis $1.2 billion per annum, amphetamines $340 million per annum, 
cocaine $138 million per annum and other illicit drugs $49 million per annum. 
 
The DALYs had to be monetised and allocated to dependent and non-dependent users. 
However, there is no information in the health datasets to attribute morbidity and mortality to 
dependent or non-dependent drug use. While some health conditions are related to chronic drug 
use, poisoning and blood-borne viruses could potentially be conditions that affect occasional 
users.  
 
Therefore, the relationships between drug use and these conditions were assumed to be a 
function of frequency of drug use: costs were allocated to dependent and non-dependent users 
on that basis. All remaining health-related costs were allocated to dependent users. 
 
Table 2: Drug-attributable disability adjusted life years (DALY), converted to annual cost, by 
illicit drug type 
 Cannabis Cocaine Opiates Amphet. Other illicit 
drugs 
Yrs lost as a result of disability 9,835 791 12,470 1,552 177 
Potential years of life lost 130 357 8,569 1,293 235 
Disability adjusted life years (a) 9,965 1,148 21,040 2,845 412 
Cost ($million) (b) $ 1,195 $ 138 $ 2,523 $ 341 $ 49 
Dependent users ($ million) $ 1,195 $ 113 $ 2,386 $ 274  
Non-dependent users ($million) $ 0.067 $ 24.7 $ 137 $ 67.5  
Notes: 
(a) Equals: YLD + YLL 
(b) Equals: DALYs *$119,937 (2005 equivalent of $108,000 in 2002 prices) 
Components may not sum to total due to rounding 
See Appendix 1 for detailed calculations 
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CRIME EFFECTS 
 
This section reports on the estimated crime costs associated with different drug types for 
dependent and non-dependent users. 
 
There is clearly an association between illicit drugs and criminal activity. For example, in Australia 
approximately 70% of arrestees have used illicit drugs within the past month, and nearly all 
arrestees have used illicit drugs in their lifetime (Schulte, Mouzos & Makkai, 2005). However, it is 
difficult to determine whether drug use causes crime, crime causes drug use, or both drug use and 
crime are caused by other factors (MacCoun, Kilmer & Reuter, 2003). 
 
Goldstein (1985) identified three ways in which drugs can be causally related to crime: 1) via the 
psychopharmacological effects of the drugs on the drug user (e.g., through intoxication); 2) to 
finance drug purchases (“economic compulsive crime”); and 3) in the operation of drug markets 
and drug distribution (“systemic crime”). 
 
In Australia, arrestees interviewed in the Drug Use Monitoring in Australia (DUMA) project are 
asked about their drug-taking and criminal behaviour. For several years, detainees in seven police 
stations across four jurisdictions (NSW, Queensland, South Australia and Western Australia) 
have been asked about their drug use and criminal activity, and asked to provide urine to check 
self-reported drug use (Schulte et al., 2005). They are also asked to assess the extent to which 
drug use caused their crimes.  
 
DUMA self-reported criminal activity was used by Collins and Lapsley (2002) to attribute a 
proportion of the social costs of crime to drug use. They applied these fractions to the costs of 
policing, criminal courts, prisons, customs, national law enforcement agencies, reduction in the 
value of stolen property, foregone productivity of criminals, and healthcare and mortality 
resulting from violent crimes. They estimated nearly $3 billion in crime costs could be attributed 
to illicit drugs, and a further $1.2 billion jointly attributed to illicit drugs and alcohol.  
 
The approach adopted here is broadly similar to that of Collins and Lapsley (2002). A question 
DUMA respondents are asked is: “What proportion of your crime was related to drug use 
(except alcohol)?” 
 
When respondents wholly or partially attribute their criminal activity to drug use, this attribution 
is allocated to particular drug types and then valued in monetary terms.  Self-reported drug use 
was used; comparisons of self-report with urine drug screens have shown general concordance 
(McGregor & Makkai, 2003). It should be noted that the focus on DUMA and drug use means 
systemic crime is omitted, as it is related to drug supply rather than drug use. 
 
Data and methods 
The Australian Institute of Criminology provided access to unit record data of the Drug Use 
Monitoring in Australia (DUMA) project. In 2005, there were 3,786 individuals from whom 
information was collected. There were 250 records where necessary data were missing. The 
remaining 3,536 individuals had a total of 9,010 criminal charges, classified using the Australian 
Bureau of Statistics’ Australian Standard Offence Classification (ASOC).  
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The ASOC categories were grouped into broader offence categories, which were then allocated 
to one of three groups. The first were crimes that clearly generate social costs, such as property 
and violent crimes. The second were crimes which relate to crimes that generate social costs but 
do not directly create social costs themselves, such as parole violations, driving offences and 
weapons charges (and illicit drug offences). In the third group were offences thought to create 
only negligible social costs, such as offensive behaviour. The first group were the only offences 
valued for this exercise; they matched all crime categories included in Mayhew’s (2003) estimate 
of the social costs of crime (except illicit drug offences). 
 
The following approach to calculate proportions of offences to particular types of drugs was 
used: 
• To the question about how many offences were drug-related, responses were quantified as 
follows: “All of them” was considered 100%; “Most of them” was considered 75%; 
“About half of them” was considered 50%; “Some of them” was considered 25%; and 
“None of them” was considered 0%; and 
• The frequency with which the different types of illicit drugs had been consumed over the 
month before arrest (i.e. the number of days used in the past month) was used to allocate 
the crime to particular types of drugs.  
 
There are several assumptions involved in this approach. First, that self-reported attribution is 
accurate (It has been argued that self-reported causal effects may overstate the actual size of the 
effect; Best et al., 2001; McGregor & Makkai, 2003). Second, that the quantification of the 
attribution matches the attribution respondents had in mind. It has been difficult to ensure that 
DUMA respondents understand the question correctly, and there have been several efforts to 
improve the accuracy of responses over time. Third, that each individual’s drug using and 
criminal behaviour is consistent over the past 12 months: respondents are asked to make their 
attribution about crimes over the past 12 months; past month drug consumption was used to 
make allocations between different types of drugs; and the crime(s) being considered are the ones 
for which the individual has just been apprehended. Fourth, it is assumed that DUMA detainees 
are representative of those committing crimes in Australia (for both reported and unreported 
crimes). 
 
In a number of cases, respondents attributed part or all of their criminal behaviour to illicit drug 
use but had consumed no illicit drugs over the past month. This is possible, as some arrests are as 
a result of an arrest warrant, where the offence may have occurred more than 30 days prior to 
arrest. Despite this, in these cases the attribution was removed. While this was a pragmatic 
decision, as it was impossible to follow the selected attribution strategy, it also addresses some of 
the concerns about respondents overstating the role of drugs in their criminal activity, as doubts 
about attributions are likely to be greatest in such cases (and arrest warrants comprised a minor 
component of overall arrests). 
 
The method of allocating the attributed portion of a crime to particular drugs was different 
depending on whether or not the crime was judged to be primarily economic compulsive in 
nature (i.e. whether the crime was committed to obtain income). For crimes judged to be 
economic-compulsive, such as theft and fraud, attribution should be based on an offender’s 
expenditure on particular types of drugs. However, there was no information on the amount 
spent or the number of times a drug had been used in DUMA or in any other dataset that could 
be considered to cover the same population.  
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The attribution was assigned to drugs consumed on the basis of days used in the past month. The 
only adjustment made was that days of use of marijuana were given a weighting of one half, as it 
is significantly cheaper that the other common illicit drugs (ACC, 2005). For example, if a 
respondent used marijuana on ten days, amphetamines on ten days and opiates on five days, then 
the total weighted days is 20 (as marijuana has only five “weighted days”) and 25% of the costs of 
that crime is allocated to marijuana, 50% to amphetamines and 25% to opiates. 
 
For crimes that were not primarily economic compulsive, it was arguable that all drugs should be 
given equal weight. Cannabis, a drug used within the past month by 56% of DUMA detainees in 
2005, has been shown to inhibit aggressive behavior and thus may not be a significant 
contributor to violent crime (White & Gorman, 2000). Pacula and Kilmer (2003) analysed 
Arrestee Drug Abuse Monitoring data (the United States equivalent to DUMA) and found a 
causal relationship between marijuana and income-producing crime but not violent crime. In line 
with that finding, the approach adopted here was to exclude cannabis from the attribution of 
violent crime. All other drugs were given equal weight in the self-reported drugs-crime 
attribution, based on the number of days used in the past month. This may understate or 
overstate the role of some other drugs, but there is a dearth of studies that could be used to 
determine how such allocations should be made more precisely. 
 
Crime cost estimates were taken primarily from Mayhew (2003), an Australian Institute of 
Criminology study that estimated the total costs of crime in Australia. The breadth of the study 
and the steps undertaken to adjust for measurement issues – particularly the underreporting of 
crime – make it the best available resource for such information. The frequencies of crimes were 
updated using Australia Bureau of Statistics data. The costs, which were assumed to be in 2002 
prices, were updated using the same chain price index figures used in the previous section (ABS, 
2006a). 
 
The analysis of the costs was done separately for DUMA respondents classified as drug 
dependent and non-dependent respondents. DUMA includes six questions about drug 
dependence. These questions reflect DSM-IV criteria, and a respondent is classified as dependent 
if they meet three or more of these criteria (Schulte et al., 2005). 
 
Results 
The detailed calculations for crime costs are provided in Appendix 2. The calculations are made 
for crimes considered to be primarily income generating and then for other crimes that generate 
social costs. The totals for these two broad categories by drug types and the overall crime costs 
are shown in Table 3. 
 
The total social cost of drug-attributable crimes is estimated to be nearly $7.5 billion per annum. 
Offenders classified as drug dependent are estimated to generate $6.8 billion in crime costs, more 
than 90% of the annual total crime costs. The annual crime costs generated by amphetamine use 
were estimated to be approximately $3 billion, cannabis $1.9 billion, opiates $1.7 billion, cocaine 
$160 million and other illicit drugs approximately $600 million. 
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Table 3: Drug-attributable crime calculated as annual social cost ($million), by illicit drug type  
 Cannabis Cocaine Opiates Amphet. Other 
illicits (a) 
Income-generating 
offences 
     
Dependent users $ 1,601 $ 105 $ 1,551 $ 2,203 $ 325 
Non-dependent users $ 319 $ 26.1 $ 28.4 $ 204 $ 55.6 
Total cost $ 1,919 $ 131 $ 1,579 $ 2,407 $ 380 
Other offences      
Dependent users $ 0 $ 30.2 $ 163 $ 592 $ 196 
Non-dependent users $ 0 $ 0.63 $ 1.16 $ 39.8 $ 12.7 
Total cost $ 0 $ 30.8 $ 164 $ 632 $ 209 
Total crime costs      
Dependent users $ 1,601 $ 135 $ 1,714 $ 2,795 $ 521 
Non-dependent users $ 319 $ 26.7 $ 29.6 $ 244 $ 68.3 
Total cost $ 1,919 $ 162 $ 1,743 $ 3,039 $ 589 
Notes: 
(a) Other illicit drugs include: hallucinogens/LSD; benzodiazepines; ecstasy; and non-prescribed 
methadone 
See Appendix 2 for detailed calculations 
Components may not sum to total due to rounding 
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ROAD ACCIDENTS 
 
Collins and Lapsley (2002) estimated that the cost of drug-attributable road accidents was $532 
million in 1998-99. This was based on Ridolfo and Stevenson’s (2001) attributable fractions, 
which estimated that 0.008 of road accidents could be attributed to the use of amphetamines and 
0.007 could be attributed to the use of opiates.3 No causal relationship was reported for cannabis, 
cocaine or other illicit drugs. 
 
This broadly accords with international research. Movig et al. (2004) tested drivers for drug use in 
The Netherlands and compared the results to accident information. They found no effect of 
cannabis, and effects for amphetamines, cocaine and opiates that were not statistically significant 
(significant effects were found for alcohol and benzodiazepines). The prevalence and profile of 
cocaine use in Australia is different to many other countries, and may explain the lack of an 
association. 
 
Collins and Lapsley’s (2002) estimate was updated on the basis of ABS (2006a) and split between 
amphetamines and opiates on the basis of the relative weighting in Ridolfo and Stevenson (2001). 
The total social cost was estimated to be $651 million, with $351 million attributed to 
amphetamines and $307 million to opiates. 
 
There is no obvious basis for distinguishing between road accident costs created by those who 
are drug dependent and those who are not. Like some of the health conditions, the relationship 
between drug use and road accidents was assumed to be a function of frequency of use. Costs 
were allocated between dependent and non-dependent users on that basis, using estimates 
reported in the later results section. The results are shown in Table 4. 
 
Table 4: Annual road accident cost attribution between dependent and non-dependent users 
 Opiates Amphetamines 
Costs of road accidents ($million) $ 307 $ 351 
Proportion of doses – dependent (a) 85% 58% 
Road accident costs – dependent ($million) $ 261 $ 203 
Proportion of doses – non-dependent (a) 15% 42% 
Road accident costs – non-dependent ($million) $ 45.6 $ 148 
Notes: 
(a) Taken from the estimates reported in Results section 
Sources: Collins & Lapsley (2002); ABS (2006a) 
                                                 
3 Road accidents effects were not estimated by English et al. (1995) and therefore not included in Mathers et al. (1999): there is no overlap between these 
costs and the health costs in the earlier section. 
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WELFARE AND LABOUR MARKET EFFECTS 
 
Drug use can have an effect on the labour market outcomes of drug users, in terms of reduced 
productivity, lower wages, higher unemployment and greater reliance on welfare. Collins and 
Lapsley (2002) used information from the Federal Department of Family and Community 
Services (FACS) to estimate these costs. FACS identified a group of people receiving 
unemployment benefits who were exempt from activity test requirements because of an 
identified alcohol or other drug dependency. Collins and Lapsley (2002) also used information 
about the proportions of people accessing the Supported Accommodation Assistance Program 
for whom substance abuse was the main reason for doing so. 
 
In these estimates, the causal relationships are assumed rather than established. Studies have 
differed as to whether illicit drug use affects labour market outcomes. DeSimone (2002) found 
marijuana use reduces employment probabilities for men in the United States, Kaestner (1994) 
found negative wage effects of cannabis (for men and women) and cocaine (for men only) in the 
United States, and Van Ours (2005) found frequent cannabis use (but not cocaine use or 
infrequent cannabis use) has a negative wage effect in the Netherlands. Other studies are 
inconclusive (e.g. MacDonald & Pudney, 2001) or find, perhaps surprisingly, a positive 
relationship between illicit drug use and wages or employment (e.g. Kaestner, 1991; Gill & 
Michaels, 1992). 
 
In the main estimate, no labour-related costs are included. In the sensitivity analysis, the upper 
estimate is based on negative relationships between drug use and employment outcomes for 
dependent drug users, and valued in terms of the average wage. 
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PREVALENCE ESTIMATES 
 
Estimating the prevalence of illicit drug use is difficult. The most common method is to 
extrapolate household survey results. That is certainly possible in Australia: the National Drug 
Strategy Household Survey (NDSHS) has been conducted by the Australian Institute of Health 
and Welfare (AIHW) periodically since 1985. 
 
However illicit drug use, which is more common amongst people in marginalised populations, is 
likely to be underestimated on this basis (Hall et al., 2000; Dietze, Hickman & Kimber, 2005). 
There are some Australian epidemiological studies that use alternative methods to estimate the 
prevalence of frequent or problematic use; these provide additional sources of information. 
 
In these epidemiological studies, distinctions are generally made between two types of drug users: 
1) “frequent” users (alternatively labelled “regular”, “problematic” or “dependent” users); and 2) 
“infrequent” users (alternatively labelled “occasional”, “recreational” or “nondependent” users). 
The “frequent” and related labels tend to refer to daily, or near-daily, drug users (Hall et al., 
2000). Some studies include more than one of these classifications; for example, McKetin et al. 
(2005) estimates the number of dependent and regular amphetamine users. (Whenever this 
occurs, estimates of the number of “dependent” drug users will be used.) “Infrequent” users are 
characterised as people who generally use no more than one or two days a week, primarily in 
social settings. 
 
The approach taken is as follows. Wherever available, studies using indirect estimation techniques 
are used to estimate the number of dependent drug users. Judgements are then made about the 
proportion of dependent drug users likely to overlap with the National Drug Strategy Household 
Survey estimates, and the remainder of the NDSHS-based figures are used to estimate the 
number of non-dependent users. All of the results are summarised in Table 5. 
 
Table 5: Illicit drug prevalence estimates, by level of dependence and illicit drug type 
 Cannabis Cocaine Opiates Amphet. 
Dependent drug users 247,500 13,892 41,401 73,257 
Non-dependent drug users 1,662,575 162,454 107,898 495,500 
All illicit drug users 1,910,075 176,346 149,299 568,757 
 
Opiate/heroin users 
Dependent heroin users 
Recent epidemiological estimates of the number of heroin users in New South Wales and 
Victoria were combined and extrapolated to develop an estimate of the number of frequent 
heroin users in Australia. Dietze, Hickman and Kimber (2005) estimated the prevalence of 
problematic heroin use in Melbourne in 2003/04, while Degenhardt, et al. (2004) estimated the 
number of regular heroin users in New South Wales in 2002. Combining estimates from different 
years was not expected to lead to too much additional variation, as there were only small changes 
to other heroin usage indicators between 2002 and 2003 (Breen et al., 2004). 
 
These estimates were averaged and extrapolated to other Australian jurisdictions on the basis of 
the number of fatal overdoses in each jurisdiction in 2003 (Degenhardt, Roxburgh & Black, 
19 
SOCIAL COSTS BY DRUG TYPE 
2004). That yielded an estimate of the number of regular heroin users in Australia in 2003 of 
41,400 (for more details, see Moore et al., 2005). 
 
Other heroin users 
Weatherburn and Lind (1995) applied simple ratios of the number of recreational to regular 
heroin users to estimate that there were between 72,000 and 450,000 recreational users, while 
Hall et al. (2000) used Hepatitis C epidemiological studies to estimate that there were between 
148,000 and 222,000 non-regular heroin users in Australia. Estimates from the NDSHS are much 
smaller, with AIHW (2005) estimating that 56,300 of Australian had used heroin within the past 
12 months. 
 
Here, the dependent users estimates were used in combination with household survey figures to 
develop a range of estimates for the number of occasional heroin users. AIHW (2005) provides 
estimates of the number of Australians who had used heroin in the week (11,000), month 
(15,000) and year (56,300). A conservative approach would be to assume that all those who had 
used heroin in the past week were dependent users. Non-dependent users identified by the 
NDSHS is therefore 45,300 (56,300 – 11,000). Keeping the assumption that weekly users were 
dependent, but using an alternative assumption that the NDSHS misses as many non-dependent 
users as dependent users (i.e. that it identifies 11,000 of 41,400), the estimate becomes 170,000. 
The midpoint of the low and high estimates is 108,000. This is used as the main estimate. 
 
Amphetamine users 
Dependent amphetamine users 
Many regular methamphetamine users, like heroin users, belong to marginal populations and are 
unlikely to be commonly represented in household surveys. McKetin et al. (2005) estimated the 
number of regular and dependent methamphetamine users via an indirect prevalence estimation 
technique, using treatment, hospital and arrest data. Estimates were based on a survey of 310 
regular methamphetamine users recruited from across Sydney between December 2003 and July 
2004. 
 
They estimated that the number of dependent methamphetamine users in Australia – with 
dependence assessed as a score of four or greater on the Severity of Dependence Scale – was 
approximately 73,000. This was the median estimate of the five estimates they developed (three 
based on hospital admissions, one on treatment, and one on arrests). 
 
Other amphetamine users 
Amphetamine and methamphetamine use in Australia is more prevalent than heroin, and 
therefore likely to be better estimated by household surveys. For example, 97,000 people had 
used amphetamines or methamphetamines (it is combined in the survey) in past week in the 2004 
NDSHS, which accorded much more closely with the indirect dependence estimate than did the 
heroin figure. 
 
AIHW (2005) estimated that the number of Australians who had used amphetamines over the 
past year was 532,000. It was estimated that only half of the dependent users had been identified 
in the NDSHS, so 532,000 less the half of the number of dependent users (i.e. 36,500) results in 
an estimate of 495,500 non-dependent amphetamine users. 
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Cannabis users 
Dependent cannabis users 
Teesson et al. (2002) used a survey of general population to estimate that 1.5% of the general 
population was dependent on cannabis. Applying this proportion to the Australian population of 
those aged above 14 years old (as estimated in AIHW, 2005) results in an estimate of 247,000 
dependent cannabis users in Australia. 
 
Other cannabis users 
The AIHW (2005) estimated that the number of Australians who had used cannabis over the past 
year was 1,848,200. Cannabis is more prevalent than other illicit drugs, so it is estimated that only 
one-quarter of dependent cannabis users (i.e. 61,000) would not have been identified in the 
NDSHS. Therefore it is estimated there is 1,662,000 non-dependent cannabis users in Australia. 
(Using the household survey to estimate the number of dependent users and then assuming some 
of them are missed in the survey is problematic, but unavoidable.) 
 
Cocaine users 
Dependent cocaine users  
There is little information on the number of cocaine users in Australia. Shearer et al. (2005) 
researched several aspects of cocaine supply, but they did not specifically consider the question of 
the number of users (they used the NDSHS figures for a market estimation). Some of 
characteristics from Shearer et al. (2005) are combined with NDSHS figures to develop an 
estimate. 
 
The 2004 NDSHS estimates were that 24,700 Australians had used cocaine in the past week and 
53,000 had used it in the past month. Shearer et al. (2005) found that 36% of their face-to-face 
sample was dependent on cocaine. The 36% figure was applied to the users of the past week and 
month to get estimates of 8,800 and 19,000. The midpoint of these was used: it was estimated 
there were 14,000 dependent cocaine users in Australia. 
 
Other cocaine users 
The AIHW (2005) estimated that the number of Australians who had used cocaine over the past 
year was 169,400. It was assumed that only half of the dependent users had been identified in the 
NDSHS, so removing the other half (i.e. 7,000) results in an estimated 162,200 non-dependent 
cocaine users. (Again, using the household survey to estimate the number of dependent users and 
then assuming some of them are missed in the survey is problematic, but unavoidable.) 
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CONSUMPTION-BASED MARKET ESTIMATES 
 
Consumption-based estimates are made for opiates, amphetamines, cocaine and cannabis. In 
surveys of drug users, respondents are generally not asked about the weights of illicit drugs they 
consume. Instead, they are normally asked about the number of days or times they use particular 
drugs over a recent period, such as a week or a month. To develop a consumption-based 
estimate, this information needs to be combined with information on the amount consumed on 
each occasion, the average purity of the drug and the number of users. The parameters and 
estimates are shown in Table 6. This approach is obviously an information-intensive approach, 
and the use of several uncertain parameters leads to some significant uncertainties. These figures 
should be used together with the lower and upper estimates. 
 
Heroin consumption 
Frequency of heroin use – dependent users. Weatherburn and Lind (1995) estimated that regular users 
inject 2-3 times per day and used an average of 17.5 times per week in their estimate. This was 
adopted by Hall et al. (2000), and subsequently by Degenhardt et al. (2004a). Dietze et al. (2003) 
collected a convenience sample of 1001 regular injecting drug users recruited from sites in 
Melbourne, Sydney and South Australia. Respondents had used an average of 11.2 times over the 
past week and 49.2 times over the past month, with a standard deviation in both cases greater 
than the average. Dietze et al. (2003), the more recent estimate, is adopted for the main estimate 
(i.e. 11 injections per week). 
 
Frequency of heroin use – non-dependent users. Weatherburn and Lind (1995) estimated that infrequent 
heroin users tended to use primarily on weekends, at an average frequency of once per week or 
once per fortnight. This was adopted by Hall et al. (2000), and subsequently by Degenhardt et al. 
(2004). It is therefore estimated that nondependent users injected heroin at an average rate of 
0.75 injections per week (i.e. the midpoint of once per fortnight and once per week). 
 
Amount of impure heroin used per injection. Heroin “caps” are typically used in a single injection 
(Darke, Topp, Kaye & Hall, 2002; Breen et al., 2004). However, there is little agreement on the 
weight of a cap of heroin: for example, Maher and Dixon (1999: 490) describes caps as “small 
units weighing between 0.02 and 0.03 grams”, while the Australian Crime Commission uses a 
weight range of between 0.1 and 0.3 of a gram of impure heroin for a “cap” (e.g. ACC, 2005). 
Moore et al. (2005) considers these figures and information on the weight of heroin seized in 
Victoria to estimate a dose at 0.05 gram, with a range of between 0.03 and 0.12 grams. 
 
Purity of heroin used. Purity information is taken from Victorian data, which is seemingly 
representative of Australian purity levels. In 2003, the average purity was 24% (Moore et al., 
2005). 
 
Amount of pure heroin consumed. These elements can be used to estimate the amount of pure heroin 
consumed by dependent heroin users in Australian each year. The best estimate is that 
approximately 340 kilograms of pure heroin is annually consumed in Australia. 
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Table 6: Estimates of the annual quantity consumed in pure terms (except cannabis), by illicit 
drug type 
 Cannabis(a) Cocaine Opiates Amphet. 
Estimated number of annual doses     
Dependent drug users 247,500 13,892 41,401 73,257 
Weekly use– dependent (b) (b) 11 7 
Non-dependent drug users 1,662,575 162,454 107,898 495,500 
Weekly use – non-dependent (b) (b) 0.75 0.75 
Weekly use-all users (b) 3.29 (b) (b) 
Total times used weekly (c) (b) 580,178 536,335 884,424 
Total times used annually (d) (b) 30,169,258 27,889,410 45,990,048 
Other parameters     
Amount per dose (grams) (b) 0.05 0.05 0.05 
Average purity (%) (e) 55% 24% 25% 
Total pure amount (kilograms) (f) 281,501 (g) 830 335 575 
Notes: 
(a) The cannabis estimate is based on Clements and Daryal (1999), and is therefore not constructed from 
the prevalence and dose parameters 
(b) Not required for the calculation for that illicit drug type 
(c) For amphetamines and opiates, this equals: (Dependent drug users)*(Weekly use – dependent) + 
(Non-dependent drug users)* (Weekly use – nondependent). For cocaine, this equals: [(Dependent 
drug users) + (Non-dependent drug users)] * (Weekly use – all users). 
(d) This equals the previous row times 52 
(e) No purity measurement was available for cannabis 
(f) Equals: (Total times used annually) * (Amount per dose) * Average purity / 1000 [to convert grams to 
kilograms] 
(g) This is an impure estimate 
 
Amphetamine consumption 
Frequency of amphetamine use – dependent users. McKetin et al. (2005) reports that 82% of their 
respondents had used methamphetamine weekly or more often. AIHW (2005) reported that 
95,000 had consumed amphetamines weekly or more often. In the absence of further 
information, dependent users were assumed to use amphetamines daily.  
 
Frequency of amphetamine use – non-dependent users. Weatherburn and Lind’s (1995) assumption for 
heroin users of occasional use of between once per week or once per fortnight was applied to 
nondependent amphetamine users. It was in general accord with the frequencies observed in the 
NDSHS (AIHW, 2005). 
 
Amount of impure amphetamine used per injection. “Caps” are also used to estimate amphetamine 
consumption (it also comes in other forms). As a result, the same average dose of 0.05 gram 
applied to heroin is also used here. 
 
Purity of amphetamine used. Purity information is taken from the Australian Crime Commission 
(2006). Across Australia, the purity of amphetamine police seizures smaller than 2 grams was 
approximately 25%. 
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Amount of pure amphetamine consumed. Together, these elements can be used to estimate the amount 
of pure amphetamines consumed in Australia each year. The best estimate is that approximately 
574 kilograms of pure amphetamines is consumed annually. 
 
Cocaine consumption 
Frequency of cocaine use. Shearer et al. (2005) asked survey questions that enabled the calculation of a 
“Q score”, which is an estimate of the average number of times per day a drug is consumed. The 
results were that their Sydney respondents consumed cocaine 0.72 times per day and Melbourne 
respondents consumed cocaine 0.21 times per day. These were averages for both dependent and 
non-dependent cocaine users. While the Melbourne estimate is perhaps more representative of 
other Australian locations, Sydney has more cocaine users (Shearer et al., 2005). Therefore a 
simple average of these values (0.47 times per day) is applied to the estimated number of cocaine 
users. 
 
Amount of impure cocaine used per injection. “Caps” are also typically used in cocaine injections, and 
are used by Shearer et al. (2005) in their market sizing calculations. While they use 0.1 gram, it is 
likely that caps of cocaine are similar to those of heroin. Therefore a dose of cocaine is estimated 
to be 0.05 gram, with a range of between 0.03 and 0.12 grams. 
 
Purity of cocaine used. According the Australian Crime Commission (2006), the median purity of 
cocaine less than 2 grams was 53.8% in Melbourne and 58% in Sydney. On this basis, a purity 
level of 55% for cocaine was adopted. 
 
Amount of pure cocaine consumed. These elements result in an estimate for the amount of pure 
cocaine of 788 kilograms. 
 
Cannabis consumption 
Clements and Daryal (1999) estimated the amount of marijuana consumed in Australia between 
1988 and 1995. This estimate is updated, based on the number of marijuana users recorded in the 
2004 NDSHS and the 1995 NDSHS numbers used by Clements and Daryal (1999). On this 
basis, it is estimated that approximately 281,501 kilograms of marijuana is consumed in Australia. 
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RESULTS 
 
All of the estimated social costs (health, crime and road accidents) are presented in Table 7. The 
annual social costs of drug use in Australia are estimated to total approximately $12 billion in 
these calculations. Crime costs represent the majority of all costs. Dependent opiate ($4.4 billion), 
amphetamines ($3.3 billion) and cannabis ($2.8 billion) users account for more than 80% of all 
social costs. 
 
Table 7: Total social costs per year ($million), by illicit drug type 
 Cann. Cocaine Opiates Amphet. Other All drugs 
Health effects       
Dependence-related $ 1,195 $ 113 $ 2,386 $ 274 n.a. $ 3,968(a) 
Non-dependence 
related 
$ 0.067 $ 24.7 $ 137 $ 67.5 n.a. $ 229(a) 
All use $ 1,195 $ 138 $ 2,523 $ 341 $ 49.4 $ 4,247 
Crime costs       
Dependence-related $ 1,601 $ 135 $ 1,714 $ 2,795 $ 521 $ 6,765 
Non-dependence 
related 
$ 319 $ 27 $ 30 $ 244 $ 68.3 $ 687 
All use $ 1,919 $ 162 $ 1,743 $ 3,039 $ 589 $ 7,453 
Road accident costs       
Dependence-related $ 0 $ 0 $ 261 $ 203 $ 0 $ 464 
Non-dependence 
related 
$ 0 $ 0 $ 45.6 $ 148 $ 0 $ 193 
All use $ 0 $ 0 $ 307 $ 351 $ 0 $ 658 
Total costs       
Dependence-related $ 2796 $ 248 $ 4361 $ 3,272 $ 52(a) $ 11,198(a) 
Non-dependence 
related 
$ 319 $ 51 $ 212 $ 459 $ 68(a) $ 1,110(a) 
All use $ 3,115 $ 300 $ 4,574 $ 3,731 $ 638 $ 12,357 
Notes:  
(a) These totals omit the health costs associated with the Other drugs category, as those costs are not 
disaggregated by dependence 
n.a. = Not available 
Components may not sum to total due to rounding 
 
Social costs per drug user 
The prevalence estimates are combined with the above cost estimates to estimate the social costs 
per drug user for amphetamines, cannabis, cocaine and opiates (see Table 8). In all four drug 
categories, the estimated social cost per dependent user is much higher than the social cost per 
non-dependent user. The estimated cost per dependent opiate user is estimated to be over 
$100,000, more than the social costs of $45,000 per dependent amphetamine user, $18,000 per 
dependent cocaine user and $11,000 per dependent cannabis user. Non-dependent drug users 
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generate much lower costs, with the non-dependent opiate use of $2,000 being the highest of 
these estimates. At the other end, cannabis is estimated to have average annual costs per non-
dependent user of $192.00. 
 
It should be remembered that it is not possible to specifically consider people who use or are 
dependent on more than one type of illicit drug. In the way the analysis has been conducted, the 
average costs for such individuals can be estimated by adding up the social costs of the various 
drug types they use or are dependent on. For example, it is estimated that, on average, a non-
dependent user of both cannabis and amphetamines generates social costs of approximately 
$1,100 per annum. The average social costs generated by some polydrug users could be 
substantially more than any one estimate in Table 8. 
 
Table 8: Annual social costs per drug user, by level of dependence and illicit drug type 
 Cannabis Cocaine Opiates Amphet. 
Dependent drug users 
Costs – dependence ($million) $ 2,796 $ 248 $ 4,361 $ 3,272 
Number of users 247,500 13,892 41,401 73,257 
Social cost per dep. user ($) $ 11,296 $ 17,872 $ 105,342 $ 44,661 
Non-dependent drug users 
Costs – non-dependence ($million) $ 319 $ 51 $ 212 $ 459 
Number of users 1,662,575 162,454 107,898 495,500 
Social cost per non-dep. user ($) $ 192 $ 316 $ 1,967 $ 927 
All drug users 
Total costs- all drug users ($million) $ 3,115 $ 300 $ 4,574 $ 3,731 
Number of users 1,910,075 176,346 149,299 568,757 
Social cost per all user ($) $ 1,631 $ 1,699 $ 30,633 $ 6,560 
 
Social costs per amount consumed  
The average social costs of amphetamines, cannabis, cocaine and opiates by weight consumed are 
shown in Table 9. The average social costs per kilogram and gram are shown, as cannabis tends 
to be used and seized by police in larger quantities than the other drug categories. The results are 
for pure forms of the drug, except cannabis (as the THC content is not easily and consistently 
analysed by researchers or authorities in Australia). This means that, for example, the weight of 
retail-level transactions of amphetamines and opiates need to be approximately divided by four to 
get the drugs in a similar form to that shown in this table. 
 
There are significant differences in social costs by weight, with the illicit drugs that generate the 
largest social costs generally being consumed in the smallest quantities. The best estimates put the 
social costs for a kilogram of heroin at nearly $14 million, more than 1,000 times the estimated 
social costs for a kilogram of cannabis (approximately $1,000 per kilogram). The amphetamine 
estimate is also large, with social costs of $6.5 million per kilogram of pure amphetamine 
consumed. 
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Table 9: Annual social costs per pure kilogram and pure gram, by illicit drug type 
 Cannabis Cocaine Opiates Amphet. 
Total costs – all drug users($) $ 3,115 $ 300 $ 4,574 $ 3,731 
Amount consumed per year (kg) 281,501 830 335 575 
Social cost per kilogram $ 11,064 $ 361,189 $ 13,665,679 $ 6,490,430 
Social cost per gram $ 11 $ 361 $ 13,666 $ 6,490 
 
Sensitivity analysis 
It is important to consider plausible ranges for these estimates, as the parameters used to 
calculate these are subject to significant uncertainty. For each parameter, “low” and “high” values 
are developed using additional information or, where there was a lack of alternative information, 
adjustments to the main estimate that would cover the range of likely values. The details of the 
values are provided in Appendix 3. 
 
The empirical distributions of the ranges of each parameter (i.e. individual cost categories and 
prevalence and market-sizing parameters) are generated as independent triangle distributions of 
random variables, with the main estimate as the modal value. (The distributions of the total 
values, which are the sums of the dependent and non-dependent values, are the sum of the 
dependent and non-dependent random variables.) The mean, 5% and 95% percentiles of the 
distributions from 1,000 trials done in the @RISK computer program are shown in Table 10. 
The mean is included as many of the distributions are skewed due to both many main estimates 
not lying at the midpoint of the range and the effect of combining various distributions. 
 
These distributions were then used in Monte Carlo simulations to estimate the distributions of 
the social cost per user and social cost per weight estimates.4 The mean, 5% and 95% percentiles 
of the distributions from 1,000 trials in the @RISK computer program are shown for these 
outputs in Table 11. 
 
The upper estimates are generally two to three times the lower estimates. The exceptions are the 
per weight estimates, where the ranges are wider and the upper estimates can be four times 
greater than the lower estimates. There is some overlap between the social costs per user 
estimates for cannabis and cocaine, and between the per weight estimates for amphetamines and 
opiates. This second overlap, together with the structural issues associated with combining 
current social costs with the current levels of drug use at a time when the use of both opiates and 
amphetamines is changing, makes it impossible to infer much about the relative harms of this 
drug, particularly on a per weight basis. The ordering of the other results is generally robust to 
parametric sensitivity analysis. 
                                                 
4 This involves generating a sampling distribution of results by re-running calculations with parameters generated randomly within the range of plausible 
values.  
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Table 10: Sensitivity analysis, 95% confidence intervals: Costs, prevalence, market size 
 Cannabis Cocaine  Opiates Amphet. 
Costs     
Social costs – dependent drug user     
Main estimate ($million) $ 2,796 $ 248 $ 4,361 $ 3,272 
Distribution     
Lower estimate (5% level) ($million) $ 2,162 $ 184 $ 3,377 $ 1,829 
Average of distribution (50% level) 
($million) 
$ 3,121 $ 241 $ 4,151 $ 2,942 
Upper estimate (95% level) 
($million) 
$ 4,137 $ 290 $ 4,821 $ 3,823 
Social costs – non-dependent drug 
users 
    
Main estimate ($million) $ 319 $ 51 $ 212 $ 459 
Distribution     
Lower estimate (5% level) ($million) $ 140 $ 36 $ 167 $ 279 
Average of distribution (50% level) 
($million) 
$ 260 $ 46 $ 207 $ 415 
Upper estimate (95% level) 
($million) 
$ 351 $ 56 $ 249 $ 543 
Social costs – all drug users     
Main estimate ($million) $ 3,115 $ 300 $ 4,574 $ 3,731 
Distribution     
Lower estimate (5% level) ($million) $ 2,408 $ 229 $ 3,584 $ 2,211 
Average of distribution (50% level) 
($million) 
$ 3,381 $ 287 $ 4,357 $ 3,356 
Upper estimate (95% level) 
($million) 
$ 4,409 $ 338  $ 5,042 $ 4,235 
Prevalence of drug use     
Number of dependent drug users     
Main estimate 247,500  13,892  41,401  73,257  
Distribution     
Lower estimate (5% level) 203,288 10,432 38,010 67,538 
Average of distribution (50% level) 280,497 13,892 52,026 94,445 
Upper estimate (95% level) 374,173 17,349 71,157 131,562 
Number of nondependent drug users     
Main estimate 1,662,575  162,454  107,898  495,500  
Distribution     
Lower estimate (5% level) 1,564,286 139,134 65,040 418,681 
Average of distribution (50% level) 1,662,570 162,454 107,897 508,728 
Upper estimate (95% level) 1,760,568 185,689 150,524 605,395 
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Amount consumed (pure except 
cannabis) 
Cannabis Cocaine  Opiates Amphet. 
Main estimate (kilograms) 281,501 830 335 575 
Distribution     
Lower estimate (5% level) 
(kilograms) 
173,316 532 290 505 
Average of distribution (50% level) 
(kilogram) 
406,603 1,097 596 1,010 
Upper estimate (95% level) 
(kilograms) 
698,639 1,850 1,053 1,726 
See Appendix 3 for parameter values 
29 
SOCIAL COSTS BY DRUG TYPE 
Table 11: Sensitivity analysis, 95% confidence intervals: Per user and weight estimates 
 Cannabis Cocaine Opiates Amphet. 
Per Person estimates     
Social cost per dependent drug user     
Main estimate $ 11,296 $ 17,872 $ 105,342 $44,661 
Distribution     
Lower estimate (5% level) $ 6,998 $ 12,107 $55,330 $18,258 
Average of distribution (50% level) $ 11,536 $ 17,757 $ 82,832 $32,479 
Upper estimate (95% level) $ 17,437 $ 24,548 $ 115,222 $48,757 
Social Cost per non-dependent drug 
user 
    
Main estimate $ 192 $ 316 $ 1,967 $927 
Distribution     
Lower estimate (5% level) $ 84 $ 216 $ 1,288 $534 
Average of distribution (50% level) $ 157 $ 288 $ 2,040 $824 
Upper estimate (95% level) $ 212 $ 363 $ 3,253 $1,122 
Per Weight estimates     
Social cost per kilogram     
Main estimate $ 11,064 $ 361,189 $ 13,665,679 $ 6,490,430 
Distribution     
Lower estimate (5% level) $ 4,471 $ 147,166 $ 4,099,933 $ 1,710,056 
Average of distribution (50% level) $ 9,894 $ 303,142 $ 8,503,515 $ 3,816,916 
Upper estimate (95% level) $ 19,859 $ 539,811 $ 14,890,850 $ 6,983,485 
Social cost per gram     
Main estimate $ 11.06 $ 361 $ 13,666 $ 6,490 
Distribution     
Lower estimate (5% level) $ 4.47 $ 147 $ 4,100 $ 1,710 
Average of distribution (50% level) $ 9.89 $ 303 $ 8,504 $ 3,817 
Upper estimate (95 level) $ 19.86 $ 540 $ 14,891 $ 6,983 
See Appendix 3 for parameter values 
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CONCLUSION AND DISCUSSION 
 
This exercise adds further detail to our understanding of the contribution of particular types of 
illicit drugs and drug users in creating “drug problems” in Australia. Previous social cost 
estimates have rarely allocated the costs to particular types of illicit drugs, and the ones that do 
have not distinguished between dependent and non-dependent users nor conducted sensitivity 
analysis of the results. 
 
Given the variations here to the approaches previously adopted by Collins and Lapsley (2002) 
and McFadden (2006), it is hard to know in advance what magnitude of social costs should be 
expected. It turned out, while fewer categories of social costs are included in this report, the 
overall costs are higher: $12.5 billion is more than 70% higher than Collins and Lapsley’s 
1998/99 estimate in real terms. 
 
In relative terms, the social costs allocated to the various types of drugs are perhaps as expected: 
opiates account for the largest proportion of costs, while amphetamines and cannabis also 
account for sizeable proportions. When separate estimates take account of the number and type 
of users, however, the estimates are quite illuminating. Given the wide ranges of plausible values 
in most cases, not too much should be made of all of the differences. However, there are two 
results that are both interesting and fairly robust: 1) in all cases, the costs generated by dependent 
users are far higher than those generated by non-dependent users; and 2) the social costs of 
cocaine are relatively low on a per user basis. 
 
With the first of these findings, it is the magnitude of the effects that are noteworthy. In the main 
estimate, a dependent user generates between 50 and 100 times the average social costs than a 
non-dependent user. Under any plausible characterisation, dependent users are generating the 
vast majority of social costs. It is a strong indication of the value of targeted programs. 
 
The second of these findings – the relatively low social costs generated by cocaine users – may 
highlight the limitations of an excessive focus on individual drug types. While cocaine has 
traditionally been the drug of greatest concern in the United States, heroin has generally been of 
greatest concern in Australia. While cocaine is not being used as much as amphetamines and 
opiates by those caught offending or those presenting with health problems, it seems as though 
the characteristics of the users can be as important as the type of the drug. The recent decrease in 
the availability of heroin and the increase in amphetamine use in Australia demonstrates that 
substitution effects are an important element of understanding social costs. Drug-specific 
estimates of the type made here are likely to be most helpful when combined with dynamic 
modelling, rather than being considered in isolation. 
 
Other insights result from the measurement and valuation requirements of this sort of exercise. 
First, the wide ranges suggest that sensitivity analyses are important and should be consistently 
done in these sorts of exercises. Unfortunately, none of the source documents included any 
sensitivity analysis; it would have been far better for the original analysts to select appropriate 
lower and upper limits. 
 
Second, the structural issue of combining current prevalence of use with the current effects of 
drug use is particularly problematic when the use of particular drugs has been changing rapidly. 
The apparent reduction in the use of opiates and increase in the use of amphetamines in recent 
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years makes it difficult to draw definitive conclusions from the estimates of the social costs of 
these two drugs. 
 
Third, such an exercise highlights the difficulty of combining existing epidemiological research 
into the numbers and type of drug users. The indirect prevalence estimates are generally done for 
one type of drug user. When it comes to understanding the interaction and overlap of different 
types of drug use, these provide little information on which to do this. With polydrug use quite 
common, more epidemiological studies estimating the prevalence of all different types of drug 
use would produce greater consistency. 
 
The large crime cost estimates and the difficulty in determining the size of the attribution indicate 
it is an area deserving of further research. This is also true of the links between drug use and 
labour and welfare costs.  
 
This exercise is a further step in the attempt to properly understand, in economic terms, the 
relationship between illicit drugs and the social costs borne by the Australian community. There 
are more issues to be dealt with, but it is hoped this additional information will aid government 
agencies in developing policies that minimise the amount of drug-related harm in Australia. 
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APPENDIX 1: HEALTH-RELATED CALCULATIONS 
 
The disability adjusted life years (DALY) estimate has two components: years lost as a result of a 
disability (YLD) and potential years of life lost (YLL). 
 
The YLD calculations for specific conditions are shown in Table A1.1. The estimates made by 
Mathers et al. (1999) are updated on the assumption that hospital separations are correlated with 
years lost as a result of a disability. The hospital separations included are those where the 
particular condition was judged to be the principal cause of the separation. The 1996-97 
separations were classified according to ICD-9 codes, while the 2003-04 separations were 
classified using the ICD-10 codes. These were matched using Appendix B in Collins and Lapsley 
(2002). 
 
Table A1.1: Years lost as a result of a disability (YLD), by illicit drug type (a) 
Condition 
1996 
YLDs 
Hospital 
separations 
New 
YLDs 
(b) 
Drug categories 
96-97 03-04 Cann Coca Opiate Amph Other 
Abuse, dependence, poisoning conditions 
Opiate 
dependence 
14,005 4,246 3,608  11,901 0 0 11,901 0 0 
Cannabis 
dependence 
4,416 652 1,342  9,089 9,089 0 0 0 0 
Other drug 
dependence 
1,319 3,685 6,018  2,154 609 60 74 1,372 38 
Poisoning 33 2,616 2,070  26 1 0 22 0 2 
Transmissible conditions 
Hepatitis C 151 800 58  11 0 0 7 4 0 
Hepatitis B 9 146 174  11 0 0 6 4 0 
HIV/AIDS 61 5  8  90 0 1 55 33 1 
Inflammatory 
heart disease  
6 117 158  9 0 0 5 3 0 
Birth-related and maternal conditions 
Low birth 
weight 
90 300 913  273 0 151 122 0 0 
Antepartum 
haemorrhage 
(c) 296 678  586 0 443 144 0 0 
Maternal drug 
dependence & 
Newborn drug 
toxicity (d) 
(c) 845 782 676 135 135 135 135 135 
Total 23,093 13,708 15,809 24,826 9,835 791 12,470 1,552 177 
Notes: 
(a) Components may not sum to total due to rounding. 
(b) Equals: (1996 YLDs) * (Separations 03-04) / (Separations 96-97). 
(c) Mathers et al. (1999) did not estimate DALYs for Antepartum haemorrhage, Maternal drug dependence and 
Newborn drug toxicity. It was assumed that these conditions had the same relationship between DALYs and 
hospital bed days as Low birth weight. Maternal drug dependence and Newborn drug toxicity were estimated 
together. 
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(d) There was no obvious basis for allocating these health conditions to specific drug types. They can be caused 
by illicit drugs in all categories, so were allocated equally to all five categories. 
Sources: Mathers et al. (1999); Ridolfo & Stevenson (2001); Collins & Lapsley (2002); AIHW (2006); and 
author’s calculations. 
 
The potential years of life lost were estimated directly using individual mortality data collected by 
the Australian Bureau of Statistics. The estimate was made for 2004, which is the most recent 
year for which such data were available. The results are presented in Table A1.3. 
 
Table A1.2: Drug-attributable potential years of life lost (YLL), by illicit drug type (a) 
Condition Total 
YLL 
(b) 
Fraction 
attributed 
to drugs (c) 
Drug-
related 
YLL (d) 
Drug categories 
Cann Coca Opiate Amph Other 
Abuse, poisoning conditions 
Opiates 7,192  1  7,192    7,192    
Cannabis 130  1  130  130      
Cocaine 190  1  190   190     
Amphetamine 512  1  512     512   
Hallucinogens 179  1  179      179 
Inhalants 26  1  26      26 
Transmissible conditions 
AIDS 2,247  0.013 29   0  18  11  0  
Endocarditis 465  0.14  65   1  39  24  1  
Hep B 1,764  0.29  512   6  309  190  7  
Hep non A B 3,576  0.42  1,502   16  908  556  21  
Birth-related and maternal conditions 
Antepartum 
haemorrhage 
1,129  0.037;0.012  55   42  14    
Low birth 
weight 
3,951  0.026;0.021  186  103  83    
Other 
Suicide 73  0.09  7    7    
         
Total 21,946  11,096 130  357  8,569  1,293  235  
Notes: 
(a) Components may not sum to total due to rounding. 
(b) Difference between expected age of death and actual age of death, discounted at 3% per annum. 
(c) For Antepartum haemorrhage and Low birth weight, the first fraction relates to cocaine and the second 
fraction relates to opiates. 
(d) Equals: (YLL) * (Fraction attributed to drugs). 
Sources: ABS Mortality file; Ridolfo & Stevenson (2001); Collins & Lapsley (2002); and author’s calculations. 
 
The DALYs had to be monetised and allocated to dependent and non-dependent users. 
However, there is no information in the health datasets to attribute morbidity and mortality to 
dependent or non-dependent drug use. While some health conditions are related to chronic drug 
use, poisoning and blood-borne viruses could potentially be conditions that affect occasional 
users.  
38 
SOCIAL COSTS BY DRUG TYPE 
Therefore, the relationships between drug use and these conditions were assumed to be a 
function of frequency of drug use: costs were allocated to dependent and non-dependent users 
on that basis. All remaining health-related costs were allocated to dependent users. Table A1.3 
shows the allocation for health-related costs. 
 
Table A1.3: Cost attribution between dependent and non-dependent users, $million 
 Cannabis Cocaine Opiates Amph 
Health conditions related to frequency of use (a)     
Disability adjusted life years 1 215 7,692 1,337 
Cost ($million) $ 0.1 $ 26 $ 923 $ 160 
Other health conditions (b)     
Disability adjusted life years 9,963 934 13,347 1,508 
Cost ($million)  $ 1,195 $ 112 $ 1,601 $ 181 
     
Attribution of frequency-related conditions     
Proportion of doses – dependent users (c) 55% 4% 85% 58% 
Proportion of doses – non-dependent users (c) 45% 96% 15% 42% 
     
Health costs – dependent users     
Frequency component ($million) $ 0  $ 1 $ 786 $ 93 
Other costs ($million) $ 1,195 $ 112 $ 1,601 $ 181 
Total ($million) $ 1,195 $ 113 $ 2,386 $ 274 
Health costs – non-dependent users ($million) $ 0  $ 25 $ 137 $ 68  
Notes: 
(a) Considered to be drug poisoning, Hepatitis B, Hepatitis C, HIV/AIDS and infective endocartitis/ inflammatory 
heart disease.  
(b) All other health conditions. 
(c) Taken from the estimates developed in the results section. 
Source: Abelson (2003); ABS (2006a) and previous calculations. 
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APPENDIX 2: CALCULATION OF CRIME COSTS 
 
The calculations are made separately for crimes considered to be primarily income-generating and 
then for violent or other crimes that generate social costs. None of the 11 homicide offences 
were attributed to illicit drug use, so no homicide-related costs were allocated to illicit drug use. 
All of Mayhew’s (2003) other categories were given some attribution in this approach. 
 
Income generating crime 
The offences considered to be primarily income generating were: burglary, fraud, robbery, shop 
theft, vehicle-related theft (theft from and of vehicles) and other theft (including theft from 
persons). Table A2.1 shows the number of these offences committed by a person classified as 
dependent on illicit drugs, the number committed by other persons and, within each of these 
categories, the number who partly or wholly attributed their offending to illicit drug use. As 
would be expected, dependent users more frequently attribute their offending to illicit drug use. 
 
Table A2.1: DUMA income-generating offences, by dependence and attribution 
Category 
 
Total 
offences 
Offences by dependent 
drug users 
Other offences 
 
  
Attributed 
 to drugs 
Not 
attributed to 
drugs 
Attributed 
to drugs 
Not 
attributed to 
drugs 
Burglary 388 199 60 39 90 
Fraud 488 161 56 26 245 
Robbery (injured) 229 92 42 10 85 
Robbery (non-injured) 13 7 10 0 3 
Shop theft 683 337 131 59 156 
Theft – vehicles 231 107 32 22 70 
Theft – other 70 33 23 5 9 
Source: Australian Institute of Criminology, DUMA Collection, [computer file]. 
 
As explained in Section 3, attributions were removed where no illicit drug use had occurred in the 
previous 30 days. This led to the removal of: 12 attributions for Burglary; 15 for Fraud; 4 for 
Robbery resulting in injuries to the victim; 9 for Shop theft; and 9 for Theft – vehicles. 
 
Fractions of offending attributed to drug use 
Table A2.2 contains the proportion of all offences attributed to drug use, and the individual 
fractions for cannabis, cocaine, opiates, amphetamines and other drugs. These allocations are 
based on number of days each type of drug had been used over the past 30 days, with cannabis 
receiving half of the weighting of the other drug categories. 
 
The overall fractions are high: more than 40% for Burglary, Shop theft, Theft – other, and Robbery 
where the victim was not injured. The higher fractions for offences by dependent drug users suggest 
that income-generating crime is often undertaken to finance frequent purchases of drugs. 
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Table A2.2: Fractions of income-generating crimes attributed to illicit drug use  
 
Proportion of 
all offences 
Allocation to drugs 
Cannabis Cocaine Opiates Amphet  Other 
Burglary            
Dependent 44.33% 14.20% 1.14% 12.72% 13.80% 2.47% 
Non-dependent 6.31% 3.34% 0.43% 0.28% 1.87% 0.40% 
Total 50.64% 17.54% 1.56% 13.01% 15.67% 2.87% 
Fraud             
Dependent 23.62% 6.53% 0.38% 6.00% 9.47% 1.24% 
Non-dependent 1.90% 0.56% 0.27% 0.39% 0.40% 0.28% 
Total 25.51% 7.09% 0.64% 6.40% 9.87% 1.52% 
Robbery – where the victim was injured 
Dependent 29.37% 8.83% 0.91% 6.47% 9.47% 3.68% 
Non-dependent 1.31% 0.45% 0.61% 0.04% 0.11% 0.10% 
Total 30.68% 9.28% 1.52% 6.51% 9.58% 3.78% 
Robbery – not resulting in injury to the victim 
Dependent 40.38% 10.29% 0.00% 0.00% 30.09% 0.00% 
Non-dependent 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
Total 40.38% 10.29% 0.00% 0.00% 30.09% 0.00% 
Shop theft             
Dependent 40.85% 8.76% 0.78% 16.73% 11.29% 3.29% 
Non-dependent 4.83% 2.19% 0.03% 0.46% 1.45% 0.70% 
Total 45.68% 10.95% 0.81% 17.19% 12.74% 3.99% 
Theft – personal             
Dependent 37.33% 9.88% 0.00% 8.14% 18.11% 1.20% 
Non-dependent 4.78% 2.72% 0.00% 0.00% 1.82% 0.24% 
Total 42.11% 20.64% 4.19% 0.50% 4.71% 9.72% 
Theft – vehicles       
Dependent 20.64% 4.19% 0.50% 4.71% 9.72% 1.53% 
Non-dependent 1.59% 0.33% 0.00% 0.09% 0.72% 0.45% 
Total 22.24% 4.52% 0.50% 4.80% 10.44% 1.98% 
Note: The first column is the sum of the other five columns. 
Source: Australian Institute of Criminology, DUMA Collection, [computer file]. 
 
Social costs 
These fractions in Table A2.2 are monetised using Mayhew’s (2003) valuations, updated to 2005 
using Australian chain price index figures (ABS, 2006a). In her report, the frequencies of 
recorded crime in 2001 are scaled up based on the estimated level of underreporting. ABS (2005), 
the most recent report on recorded crime in Australia, was used to update the estimates. The 
estimated costs for dependent drug use that results from these calculations are shown in Table 
A2.3.  
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The total social cost of income-generating crime is estimated to be approximately $6.4 billion, 
with $2.4 billion allocated to amphetamine use and large amounts attributed to cannabis ($1.9 
billion) and opiates ($1.6 billion). 
 
Table A2.3: Cost of income-generating crime attributed to illicit drug use ($million) 
  
All offences 
Allocation to drugs 
Cannabis Cocaine Opiates Amphet  Other 
Burglary             
Dependent 1225 392 31.4 352 381 68.2 
Non-dependent 350 185 23.7 15.7 104 22.1 
Total 1575 578 55.1 367 485 90.3 
Fraud             
Dependent 3468 959 55.6 882 1390.0 182 
Non-dependent 0 0 0 0 0 0 
Total 3468 959 55.6 882 1390.0 182 
Robbery – where the victim was injured 
Dependent 62.4 18.8 1.94 13.8 20.1 7.82 
Non-dependent 3.93 1.35 1.84 0.12 0.33 0.30 
Total 66.4 20.1 3.77 13.9 20.5 8.12 
Robbery – not resulting in injury to the victim 
Dependent 16.3 4.15 0 0 12.1 0 
Non-dependent 0.0 0 0 0 0 0 
Total 16.3 4.15 0 0 12.1 0 
Shop theft            
Dependent 416 89.2 7.96 170.5 115.0 33.5 
Non-dependent 107 48.6 0.59 10.2 32.2 15.5 
Total 523 137.8 8.56 180.7 147.2 49.0 
Theft – personal             
Dependent 258 68.4 0 56.3 125 8.29 
Non-dependent 132 75.4 0 0 50.5 6.53 
Total 391 144 0 56.3 176 14.8 
Theft – vehicle             
Dependent 338 68.6 8.13 77.1 159 25.1 
Non-dependent 39.5 8.23 0 2.33 17.8 11.2 
Total 378 76.8 8.13 79.4 177 36.3 
              
All offences             
Dependent 5784 1601 105 1551 2203 325 
Non-dependent 633 319 26.1 28.4 204 55.6 
Total 6417 1919 131 1579 2407 380 
Source: Australian Institute of Criminology, DUMA Collection, [computer file]; Mayhew (2003); ABS recorded 
crime; ABS (2006a). 
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Other offences 
The other offences that lead social costs but which are not primarily motivated by income 
reasons are offences are arson, assault and sexual assault. Mayhew (2003) distinguishes between 
assaults requiring hospitalisation, assaults resulting in an injury but not requiring hospitalisation, 
and other assaults. The Australian Standard Offence Classification codes as recorded in DUMA 
(i.e. at the three digit level) only enables a distinction to be made between assaults requiring 
hospitalisation and other assaults, so it is assumed that the attributions are the same across the 
other two categories. 
 
Table A2.4 contains information on the number of respondents, the number who were classified 
as dependent or non-dependent, and the number who partly or wholly attributed their offending 
to illicit drug use for these offences. Arson is the only offence category where numbers are small. 
 
Table A2.4: Other DUMA offences, by dependence and attribution 
Category 
 
Total 
offences 
Offences by dependent 
drug users 
Other offences 
 
  
Attributed  
to drugs 
Not 
attributed 
to drugs 
Attributed 
to drugs 
Not 
attributed 
to drugs 
Arson 13 5 2 0 6 
Assault (hospital) 265 49 61 11 144 
Assault (other) 358 84 103 12 175 
Criminal damage 233 67 51 12 103 
Sexual ass. (injured) 141 17 17 6 101 
Sexual ass. (non-inj.) 224 5 28 8 183 
Source: Australian Institute of Criminology, DUMA Collection, [computer file]. 
 
Attributions were removed where no illicit drug use had occurred in the previous 30 days. This 
led to the removal of: 2 attributions for Arson; 10 for Assault resulting in hospitalisation; 33 for 
Assault (other); 23 for Criminal damage; 11 for Sexual assault where the victim was injured; and 3 for 
Sexual assault not resulting in injury. 
 
Fractions  
Table A2.5 contains the proportion of other offences attributed to drug use, and the individual 
fractions for cannabis, cocaine, opiates, amphetamines and other drugs. These allocations are 
based on number of days each type of drug had been used over the past 30 days. 
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Table A2.5: Fractions of other crimes attributed to illicit drug use  
 Proportion of 
all offences 
Allocation to drugs 
Cannabis Cocaine Opiates Amphet  Other 
Arson             
Dependent 23.08% 0.00% 0.00% 0.00% 15.38% 7.69% 
Non-dependent 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
Total 23.08% 0.00% 0.00% 0.00% 15.38% 7.69% 
Assaults resulting in hospitalisation 
Dependent 11.04% 0.00% 0.71% 2.10% 6.37% 1.86% 
Non-dependent 1.42% 0.00% 0.04% 0.00% 1.06% 0.32% 
Total 12.45% 0.00% 0.75% 2.10% 7.43% 2.17% 
Assaults (other)             
Dependent 10.89% 0.00% 0.08% 1.99% 7.33% 1.49% 
Non-dependent 0.77% 0.00% 0.00% 0.07% 0.42% 0.28% 
Total 11.66% 0.00% 0.08% 2.06% 7.75% 1.77% 
Criminal damage             
Dependent 16.52% 0.00% 0.38% 2.85% 9.68% 3.61% 
Non-dependent 0.64% 0.00% 0.00% 0.01% 0.53% 0.11% 
Total 17.17% 0.00% 0.38% 2.86% 10.21% 3.72% 
Sexual assaults resulting in injury 
Dependent 2.66% 0.00% 0.00% 0.00% 2.08% 0.58% 
Non-dependent 0.35% 0.00% 0.00% 0.00% 0.00% 0.35% 
Total 3.01% 0.00% 0.00% 0.00% 2.08% 0.93% 
Sexual assaults (others) 
Dependent 1.00% 0.00% 0.00% 0.00% 0.86% 0.14% 
Non-dependent 0.11% 0.00% 0.00% 0.00% 0.00% 0.11% 
Total 1.12% 0.00% 0.00% 0.00% 0.86% 0.25% 
Note: The first column is the sum of the other five columns. 
Source: Australian Institute of Criminology, DUMA Collection, [computer file]. 
 
Social costs 
These fractions in Table A2.5 are monetised using Mayhew’s (2003) valuations, updated to 2005 
using Australian chain price index figures (ABS, 2006a). In her report, the frequencies of 
recorded crime in 2001 are scaled up based on the estimated level of underreporting. ABS (2005), 
the most recent report on recorded crime in Australia, was used to update the estimates.  
 
The results are presented in Table A2.6. The majority of the costs are attributed to amphetamines 
($630 million of $1,035 million), while significant amounts are also attributed to opiates and other 
drugs. 
44 
SOCIAL COSTS BY DRUG TYPE 
Table A2.6: Cost of other crimes attributed to illicit drug use ($million) 
  
All offences 
Allocation to drugs 
Cannabis Cocaine Opiates Amphet  Other 
Arson             
Dependent 64.3 0 0 0 42.8 21.4 
Non-dependent 0 0 0 0 0 0 
Total 64.3 0 0 0 42.8 21.4 
Assaults resulting in hospitalisation 
Dependent 277 0 17.9 52.8 160 46.6 
Non-dependent 25.2 0 0.63 0 18.9 5.64 
Total 302 0 18.5 52.8 179 52.2 
Assaults resulting in injury but not hospitalisation  
Dependent 75.7 0 0.57 13.8 50.9 10.4 
Non-dependent 4.88 0 0 0.44 2.66 1.78 
Total 80.6 0 0.57 14.3 53.6 12.2 
Assaults (other) 
Dependent 67.7 0 0.51 12.3 45.5 9.28 
Non-dependent 4.36 0 0 0.40 2.38 1.59 
Total 72.0 0 0.51 12.7 47.9 10.9 
Criminal damage             
Dependent 485 0 11.2 83.8 284 106 
Non-dependent 19.4 0 0 0.32 15.8 3.23 
Total 505 0 11.2 84.1 300 109 
Sexual assaults resulting in injury 
Dependent 9.85 0 0 0 7.71 2.14 
Non-dependent 0.42 0 0 0 0 0.42 
Total 10.3 0 0 0 7.71 2.56 
Sexual assaults (others) 
Dependent 1.10 0 0 0 0.95 0.15 
Non-dependent 0.02 0 0 0 0 0.02 
Total 1.13 0 0 0 0.95 0.18 
              
All offences             
Dependent 981 0 30.2 163 592 196 
Non-dependent 54.3 0 0.63 1.16 39.8 12.7 
Total 1,035 0 30.8 164 632 209 
Source: Australian Institute of Criminology, DUMA Collection, [computer file]; Mayhew (2003); ABS recorded 
crime; ABS chain price index. 
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APPENDIX 3: SENSITIVITY ANALYSIS 
 
The plausible range of values for the parameters are shown and discussed below. 
 
Table A3.1: Sensitivity analysis for health, crime, road accident and labour costs 
 Estimate  
Cost Category Low Main High Comments 
Health costs ($mill) ($mill) ($mill)  
Cannabis    Neither Mathers et al. (1999) nor 
Ridolfo & Stevenson (2001) report 
error bounds. Mathers et al. (1999) 
show the YLD calculations for 
dementia, and estimates the 
relative standard errors to be 12%. 
YLL estimates are likely to be more 
precise (Mathers et al., 1999). 
As drug attributions would have 
been more difficult and the 
monetization creates an additional 
level of uncertainty, the bounds 
were set at 25% below and above 
the main estimate for all health 
cost categories. 
Dependent drug use 896 1195 1494 
Non-dependent drug use 0.050 0.067 0.084 
All cannabis use 896 1195 1494 
Cocaine    
Dependent drug use 85 113 141 
Non-dependent drug use 18.5 24.7 30.8 
All cocaine use 103 138 172 
Opiates    
Dependent drug use 1790 2386 2983 
Non-dependent drug use 103 137 171 
All opiate use 1893 2523 3154 
Amphetamines    
Dependent drug use 205 274 342 
Non-dependent drug use 50.6 67.5 84.4 
All amphetamine use 256 341 427 
Crime costs ($mill) ($mill) ($mill)  
Cannabis    There are a number of sources of 
uncertainty: how accurate self-
attribution is, uncertainty around 
that attribution, and in the way the 
costs have been valued. 
Moore (2005) used an arbitrarily 
low estimate of one-quarter of the 
main estimate for government 
spending on crime-related costs. 
That is used here.  
The upper estimate is not likely to 
be so different from the main 
estimate. For approximately 10% 
(131 of 1,373) of the offences 
partially or wholly attributed to 
drug use, the attribution was 
removed as no drug use had 
occurred in the previous 30 days. 
There was also some uncertainty 
around the costing. To take 
account of these, the main 
estimates were increased by 20% 
to create the upper estimates. 
Dependent drug use 400 1,601 1921 
Non-dependent drug use 80 319 382 
All cannabis use 480 1,919 2303 
Cocaine    
Dependent drug use 34 135 162 
Non-dependent drug use 7 27 32 
All cocaine use 40 162 194 
Opiates    
Dependent drug use 428 1,714 2056 
Non-dependent drug use 7 30 35 
All opiate use 436 1,743 2092 
Amphetamines    
Dependent drug use 699 2,795 3354 
Non-dependent drug use 61 244 293 
All amphetamine use 760 3,039 3647 
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 Estimate  
Cost Category Low Main High Comments 
Road accident costs ($mill) ($mill) ($mill)  
Opiates    Ridolfo & Stevenson (2001) provide 
no bounds on their estimates. As 
Movig et al. (2004) had found the 
effects of the use of opiates and 
amphetamines to not be 
statistically significant, in the 
absence of further Australian 
information a responsible lower 
bound is zero. There was no clear 
rationale for calculating the upper 
bound; a sufficiently high figure 
was considered to be double the 
main estimate.  
Dependent drug use 0 261 523 
Non-dependent drug use 0 45.6 91.2 
All opiate use 0 307 614 
Amphetamines    
Dependent drug use 0 203 406 
Non-dependent drug use 0 148 295 
All amphetamine use 0 351 702 
Labour costs ($mill) ($mill) ($mill)  
Cannabis    In the main and lower bound 
estimate, labour costs are assumed 
to be zero. 
Mixed research findings make it 
difficult to select an upper bound. 
The use of some illicit drugs has 
sometimes been found to reduce 
employment probabilities of heavy 
users by as much as 15% to 17% 
(De Simone, 2002). The upper 
bound was calculated by 
multiplying the number of 
dependent drug users by 15% and 
by $50,000 (an approximation of 
the average wage in Australian in 
2005; ABS 2006b). 
Dependent drug use 0 0 1,856 
Non-dependent drug use 0 0 0 
All cannabis use 0 0 1,856 
Cocaine    
Dependent drug use 0 0 52.5 
Non-dependent drug use 0 0 0 
All cocaine use 0 0 52.5 
Opiates    
Dependent drug use 0 0 311 
Non-dependent drug use 0 0 0 
All opiate use 0 0 311 
Amphetamines    
Dependent drug use 0 0 548 
Non-dependent drug use 0 0 0 
All amphetamine use 0 0 548 
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Table A3.2: Sensitivity analysis for numbers of drug users 
 Estimate  
Drug Type Low Main High Comments 
Cannabis No. of users No. of Users No. of users  
Dependent drug 
use 
173,250 247,500 420,750 Teesson et al. (2002) 
estimated 0.7% of the 
population had a cannabis 
disorder related to abuse 
rather than dependence. This 
was used as the lower 
estimate; this and the main 
estimate were combined to 
create the upper estimate. 
Non-dependent 
drug use 
1,518,921 1,662,575 1,806,229 AIHW (2005) contains 
standard errors for the 
prevalence estimates. The 
lower bound was based on the 
95% confidence interval and 
an assumption that all 
dependent users were in the 
household sampling. The 
upper bound was based on the 
95% confidence interval and 
the assumption that half of the 
dependent users were included 
in the household sampling 
(remembering that the higher 
prevalence of marijuana 
means the NDSHS provides 
better estimates). 
Cocaine No. of users No. of users No. of users  
Dependent drug 
use 
8,832 13,892 18,952 Shearer et al. (2005) 
calculated that 36% of their 
sample was dependent on 
cocaine. The lower and upper 
estimates were calculated by 
multiplying this by the 
numbers in the NDSHS for 
those who had used cocaine in 
the past week and the past 
month (AIHW, 2005).  
Non-dependent 
drug use 
128,404 162,454 196,504 AIHW (2005) contains 
standard errors for the 
prevalence estimates. The 
lower bound was based on the 
95% confidence interval and 
an assumption that all 
dependent users were in the 
household sampling. The 
upper bound was based on the 
95% confidence interval and 
the assumption that none of 
the dependent users were 
included in the household 
sampling. 
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  Estimate   
Drug Type Low Main High Comments 
Opiates No. of users No. of users No. of users  
Dependent drug 
use 
33,827 41,401 80,847 As the main estimates for the 
numbers of dependent and 
non-dependent heroin users 
were the midpoints of plausible 
ranges, the lower and upper 
bounds were the low and high 
ends of those plausible ranges.  
Non-dependent 
drug use 
45,300 107,898 170,497 
Amphetamines No. of users No. of users No. of users  
Dependent drug 
use 
59,774 73,257 150,302 McKetin et al. (2005) 
developed five multipliers of 
the number of dependent 
amphetamine users. The 
lowest estimate was used as 
the lower estimate. The upper 
estimate used the largest New 
South Wales arrest multiplier 
(there was an anomaly in the 
Australian arrest multiplier). 
Non-dependent 
drug use 
378,887 495,500 651,807 AIHW (2005) contains 
standard errors for the 
prevalence estimates. The 
lower bound was based on the 
95% confidence interval and 
an assumption that all 
dependent users were in the 
household sampling. The 
upper bound was based on the 
95% confidence interval and 
the assumption that none of 
the dependent users were 
included in the household 
sampling. 
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Table A3.3: Sensitivity analysis for the market-sizing estimates 
 Estimate  
Drug Type Low Main High Comments 
Cannabis     
Kg Consumed 93,834 281,501 844,503 Clement and Daryal (1999) do not 
estimate error bounds. They do 
discuss two earlier estimates of 
expenditure on cannabis in Australia 
where the larger estimate was 
215% of the smaller one. 
Given this range and the large 
ranges for the other drug types, a 
large range was chosen. The lower 
estimate was one-third of the main 
estimate, while the upper range was 
three times the main estimate.  
Cocaine     
Frequency of use 
(injections per 
day) 
1.47 3.29 5.04 This range is based on the Q-scores 
(converted to weekly frequencies) in 
Shearer et al. (2005). The low 
estimate is the Q-score for 
Melbourne respondents. The high 
estimate is the Q-score for Sydney 
respondents. 
Amount per 
injection 
0.03 0.05 0.12 The ranges developed for heroin by 
using Victoria Police seizure data is 
also used as the range for cocaine. 
Purity 50% 55% 60% The purity averages are reasonably 
consistent across states and 
therefore can be regarded as 
reasonably accurate. Slightly lower 
and higher purities were used as the 
bounds.  
Opiates     
Freq of dependent 
use (weekly) 
7 11 17.5 The lower estimate is based on daily 
use. The Weatherburn & Lind 
(1995) estimate was used as the 
upper estimate. 
Freq of non-
dependent use 
(weekly) 
0.5 0.75 1 The low estimate is based on 
fortnightly use, and the high 
estimate is based on weekly use. 
Amount per 
injection 
0.03 0.05 0.12 The ranges developed for heroin by 
using Victoria Police seizure data is 
used as the range for cocaine.  
Purity 20% 24% 30% The purity averages are reasonably 
consistent across states and 
therefore can be regarded as 
reasonably accurate. Slightly lower 
and higher purities were used as the 
bounds.  
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  Estimate   
Drug Type Low Main High Comments 
Amphetamines     
Freq of use - 
dependent 
3.5 7 14 The low estimate was based on 
using every second day. The high 
estimate was based on twice daily 
use. 
Freq of use - non-
dependent 
0.5 0.75 1 The low estimate is based on 
fortnightly use, and the high 
estimate is based on weekly use. 
Amount per 
injection 
0.03 0.05 0.12 The ranges developed for heroin by 
using Victoria Police seizure data is 
used as the range for cocaine.  
Purity 20% 25% 30% The purity averages are reasonably 
consistent across states and 
therefore can be regarded as 
reasonably accurate. Slightly lower 
and higher purities were used as the 
bounds.  
 
